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The failure of whole cell and whole cell component vaccines to prevent
gonorrhea, stresses the variability of immunogenically dominant sequences of
gonococcal outer membrane proteins. Thus, different approaches to vaccine
development must be employed. Recombinant epitope vaccines provide the possibility
to immunize with invariant, immunogenically recessive sequences that would bypass
problems of variable sequence immunodominance. This project primarily focused on
the generation of antibody to a putatively surface-exposed sequence of an invariant,
immunorecessive protein using immunogens created with recombinant DNA and
synthetic peptide techniques. The sequence chosen for this project was from the
Multiple Transferable Resistance C (MtrC) lipoprotein of the gonococcal hydrophobic
efflux pump. This sequence, MtrC antigenic peptide 1 (MtrC API), was predicted to
be surface-exposed and antigenic based on computer algorithms. However, MtrC API
was too small to stimulate antibody production by itself. For this reason, a
recombinant maltose binding protein/MtrC API fusion protein was produced using the
pMAL-CRl plasmid. The fiision protein was used in conjunction with synthetic
multiple antigenic peptide systems (MAPS) immunogens to successfully generate a
highly reactive polyclonal antiserum specific for MtrC API. The MtrC API-specific
antiserum strongly recognized MAPS immunogens in an enzyme-linked
immunosorbent assay and bound native MtrC protein on Western blots.
The secondary focus of this project was to determine if the MtrC API sequence
would be useful in an antigonococcal recombinant epitope vaccine. To be useful,
MtrC API must be surface-exposed, and MtrC API-specific antiserum must inhibit
bacterial growth possibly by blocking the efflux pump, or through bactericidal activity.
Results from surface-exposure and efflux pump inhibition experiments were equivocal.
However, MtrC API-specific antiserum displayed moderate bactericidal activity,
suggesting partial surface-exposure of MtrC API.
Although surface-exposure of MtrC API could not be confirmed, the procedure
described in this project is advantageous to vaccine research for the prevention of
gonorrhea. The techniques are now available to produce antibody to invariant,
immunorecessive sequences, that avoid antibody production to variable,
inmiunodominant sequences. Moreover, antibody produced to invariant,
immunorecessive sequences can be used to determine the usefulness of those sequences
in a recombinant epitope vaccine for the prevention of gonorrhea.
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INTRODUCTION
Gonorrhea, with up to a million new cases annually, is one of the most reported
diseases in the United States (6,20). In recent years, the incidence of gonococcal
infection has increased, especially among inner city teenagers (53). Neisseria
gonorrhoeae, the causative agent of gonorrhea, is an obligate human pathogen capable
of infecting a variety of mucosal surfaces including the urethra, endocervix, pharynx,
conjunctiva, salpinges, and rectum (14,16,137). Gonococcal infection may result in an
uncomplicated, mild inflammation of the urethra or cervix (20,99). If the infection is
not treated, it may spread throughout the body, a condition known as disseminated
gonococcal infection (DGI) (24,58,94).
Gonorrheal infection does not treat genders equally. Infection in men, which is
generally apparent, is characterized by a purulent urethral discharge and pain or
irritation and is easily diagnosed and treated (14). However, if allowed to progress,
gonorrhea may lead to scarring of the urethra and epididymitis ultimately producing
sterility (14). In women, infection is often asymptomatic (33,58,80) and may cause
more serious complications. From the lower genital tract, the bacterium may ascend
the endocervical and endometrial epithelia to the upper genital tract where it may cause
salpingitis, peritonitis, and pelvic inflammatory disease (PID) (146). PID is defined as
the "acute clinical syndrome associated with ascending spread of microorganisms
(unrelated to pregnancy or surgery) from the vagina or cervix to the endometrium,
fallopian tubes and/or contiguous structures" (146). N. gonorrhoeae is instrumental in
the initiation of upper genital tract infection and may be responsible for over 25% of
1

all PID cases (8). In one study, N. gonorrhoeae was isolated from the upper genital
tract in up to 33% of the acute PID cases (95). During PID the organism may enter
and grow in nonciliated cells lining the tubal mucosa and grow, resulting in
inflammation and immune mediated tissue damage (32). Tissue damage resulting from
the inflammatory response can lead to ingrowing fibroblasts, causing scarring and
functional impairment of the fallopian tubes. Scarring takes only a matter of days and
can result in irreversible tubal occlusion, intraluminal adhesion, and deciliation of
epithelial cells leading to infertility and ectopic pregnancy (146). Once damaged by
PID, the fallopian tubes are more susceptible to reinfection (8). PID may also result in
tubo-ovarian abscess, chronic pelvic pain and hydrosalpinx (8).
N. gonorrhoeae may ascend to the upper genital tract in a variety of ways. It was
hypothesized that alterations in the cervical mucosa during menstruation or retrograde
bleeding shortly after the start of menstruation facilitate migration of bacteria into the
endometrial cavity (8,146). Furthermore, the bacterium may be introduced into the
upper genital tract by insertion of an intrauterine contraceptive device (lUCD), or by
adherence to sperm cells. James-Holmquest et al. (62,65), demonstrated the ability of
N. gonorrhoeae to attach to human sperm, a process that is enhanced in the presence
of iron. In contrast to lUCD usage, the use of oral contraceptives was associated with
a decrease in upper genital tract infection. Oral contraceptives have been shown to
limit the alteration of mucosal surfaces during menstruation (8,136), and may even
lessen retrograde bleeding into the fallopian tubes (20).
N. gonorrhoeae has several methods for avoiding the immune response. Antigenic
2

variation of the outer membrane (OM) constituents including porin (55,68,70,72), pili
(49,50,128) and lipooligosaccharide (LOS) (87,89), and phase variation of pili (49,139)
and opacity proteins (12,82,133) permits the bacterium to evade immune responses
leaving the individual susceptible to reinfection. N. gonorrhoeae can also sialylate its
LOS blocking recognition by antibodies specific for LOS epitopes (119,127).
Spontaneously released membrane blebs may also bind antibody non-productively,
protecting the bacteria from humoral responses (35).
Presently, the only means of treating a gonococcal infection is through the use of
antibiotics. However, gonococcal resistance to traditional antibiotics such as penicillin,
is becoming more frequent (144). Penicillin resistance is thought to have originated in
southeast Asia and Africa and subsequently spread by travelers (96). In the future,
resistance to more antibiotics, especially in developing areas should be expected (114).
These areas have the greatest selective pressures on gonococcal strains due to the
availability of antibiotics widiout a prescription (114) and the use of those antibiotics in
improper doses (59).
Resistance to penicillin is carried by either a plasmid or the chromosome (25,59).
Plasmid-mediated penicillin resistance was first reported in 1976 with the isolation of
penicillinase producing N. gonorrhoeae (PPNG) strains (7,98). These PPNG strains
are highly resistant to penicillin (61) and are more likely to develop resistance to other
antibiotics such as tetracycline (3) and streptomycin (7). Antibiotic resistance has made
treatment of gonococcal infection more complicated. Traditional antibiotics have been
replaced by newer antibiotics with limited success. Some of these antibiotics such as
3

ceftizoxime, cefotiaxone, and spectinomycin are effective in treatment of uncomplicated
gonococcal infection, but are expensive and present the risk of anaphylaxis (53). Some
quinolones such as ciprofloxacin and norfloxacin are also effective and tend to be less
expensive, but should not be given to pregnant women or adolescents (53).
Because of antibiotic resistance, treatment of gonococcal infection is becoming
increasingly expensive (53). N. gonorrhoeae associated DGI, meningitis, and
endocarditis require intravenous antibiotic therapy for up to one, two, and four weeks
respectively (53) creating a heavy burden for health care services. The cost of
treatment for PID alone in 1992 was estimated in excess of $4 billion (145).
There has been considerable effort to develop a functional antigonococcal vaccine.
Since humans serve as the only reservoir of N. gonorrhoeae and there is no animal
model for gonorrhea, progress in this area of research has been slow. Vaccine studies
have focused on the use of major OM components such as For (147,148), pili (123),
and Rmp (101,108) as immunogens. The following describes some of these
components.
OUTER MEMBRANE COMPONENTS
Por:
The porin protein (Por) is the major gonococcal outer membrane (OM) protein,
accounting for nearly 60% of the protein in the OM (73). Por monomers range in
molecular mass from 32,000 Daltons to 39,000 Daltons (73) and exists in two forms,
PorA and PorB. PorA and PorB polypeptides share an identical nineteen amino acid
leader sequence (9) but differ in structure and orientation in the OM. PorA is oriented
4

in the OM by its central region with 15-20 amino acids of its N-terminus and a smaller
section of its C-terminus exposed (9,73). In contrast, PorB is anchored in tiie OM by
its termini with a central exposed region as shown by proteinase K digestion (9).
For functions as a porin forming trimeric hydrophilic channels (18). It interacts
closely with reduction modifiable protein (Rmp) in a ratio of 3 Rmp proteins to 1 Por
(18,73). The significance of this relationship is undetermined, however it was
hypothesized that Rmp may stabilize the formation of Por and/or aid in its operation
(73). Although functions of Por other than porin have yet to be proven, different Por
structures have been associated with serum resistance (63,73), antibiotic resistance
(109), expression of type I or type II IgA protease (73), and variations in LOS structure
(75). Por is antigenically variable between strains but is invariant within a strain (73).
Por is a possible candidate for a vaccine since it is less variable than other OM
constituents (20,147) and antibodies directed against Por are opsonic (118). 'Self-cure'
patients have high anti-Por antibody levels (21,28), and Por specific partial immunity
has been observed in prostitutes with histories of gonorrhea infections (102).
Por vaccines are complicated by the presence of Rmp (46,147), an OM protein
closely associated with Por (47,72,73). Immunizations with porin complexed with
Rmp generated antibody reactive to Rmp (101,147). Antibody specific for Rmp
blocked binding of bactericidal antibodies (101) against Por (46,101,147), and LOS
(76,108). Weltzer et al. (148), recently used Rmp deleted mutants, and liposomes
containing Por as vaccines. These vaccines may prove more effective due to the lack
of Rmp contamination and the mimicry of Por tertiary structure in liposomes (148).
5

Pilus Protein:
Pili show both phase (82,117) and antigenic variation (20,49,128). Pilin expression
may be lost during repeated subculture, however, spontaneous reversion to pilin
expression was shown (65,139). A single organism is capable of expressing a wide
variety of antigenically distinct pili, but only one type appears to be expressed at a time
(57). This expression is controlled by a single expression locus, pilE (49,128). The
expression locus is composed of a 5' terminal sequence followed by a repeat region and
two alternating conserved and variable sequences. The first variable sequence is
characterized by short variable regions showing single amino acid changes surrounded
by strictly conserved sequences (49,128). The second variable region is larger showing
multicodon changes including insertions and deletions (49,128). Due to the degree of
alteration, the first variable region was termed the semivariable region (SV), and the
second variable region was termed the hypervariable region (HV) (49). Phase variation
involves deletion of pilin coding sequences in the expression locus (50) resulting from
recombination events within the repeat sequences of the structural gene (128).
Restoration of pilus expression is then dependent upon another recombinational event
with silent coding sequences (57,128).
Genomic analysis revealed these silent pilin coding sequences, known as pilS genes,
were scattered throughout the genome (128). PilSl, the largest of the pilS loci,
contained six individual copies of pilS connected by short repeat sequences (49). PilS
genes had structural homology with pilE showing open reading frames, and variable
pilus coding regions (49). The N-terminus was conserved among different pili and was
6

absent in the silent piiin genes (49,125). One explanation for this was proposed by
Haas et al. (49), since the N-tenninus was membrane bound and did not encode
antigenic diversity, it was not needed in silent gene copies which function in the
generation of variant pilin genes by recombination events. Evidence for this was
suggested by the distribution of variable and conserved regions of both the expression
locus and silent genes (49). The repetitive sequence preceding the pilus coding region
may serve to selectively confer variant sequences from silent pilus genes to the
expression locus (49,128). The conserved regions are thought to encode essential
functions or sequence-specific interactions of the expressed protein (17,49). Not much
is known of the mechanism of pilus gene conversion but experiments by Hagblom et al.
(50), suggested a closely linked regulation of phase and antigenic variation. By using
E. coli containing cloned gonococcal pilus genes, Hagblom and colleagues reported a
variation in sequence of pili during phase changes (50). The significance of this is not
known, but it was hypothesized that alteration of pili may allow gonococci to
adaptively adhere to different cell receptors (50).
Pili appear to be primary mediators of adhesion (20,65,137). Filiated gonococci
adhere better than nonpiliated gonococci to sperm (62,65), erythrocytes (23), epithelial
cells (106,132), neutrophils (106), vaginal epithelial cells (84), human amniotic cells
(132) and non-ciliated fallopian tube cells (86,143). By enhancing attachment to
mucosal surfaces, pili promote colonization and invasion (134) making them a likely
virulence factor. This was first described by Kellogg et al. (77), in 1963. By
inoculating male volunteers, Kellogg and colleagues demonstrated that putatively
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piliated gonococci were capable of establishing infection while putatively non-piliated
gonococci were not (77). Kellogg's observations were supported by Zhang et al.
(150), who were unable to initiate infection in volunteers with a derived non-piliated
mutant. Piliated cells may also down regulate nonspecific immune component
function. For example, piliated organisms were shown to stimulate neutrophil
respiratory metabolism (20). This depletes the neutrophil of Oj metabolites rendering
it less able to kill a cell upon ingestion (20). Pili also reduce the ability of neutrophils
to take up cells (140) but the mechanism is not understood.
Pilus vaccines should block initial bacterial attachment (67). However, a pilus
vaccine tested in Korea conferred only partial immunity to homologous strains (19).
Limited success of this pilin vaccine, combined with the phase and antigenic variation
of pili, renders the pilus a controversial candidate for vaccine development. Pili are
immunogenic (123), nontoxic (123), and share a conserved structure between strains
(49,50,128). If an invariant, functionally important sequence can be found, a pilus
vaccine might prove effective in the prevention of gonorrhea (17).
Opas:
Opacity proteins (Opa) confer an opaque appearance to colonies (133,135). There
are as many as 11 Opa proteins. A single organism may express no Opas, or up to 3
Opa proteins simultaneously, in any combination (16,113,135). The degree of opacity
is related to the number and type of Opa proteins expressed with no expression
resulting in transparency (134). Opas were associated with increased adherence to
neutrophils and other host cells (38,136) and with increased sensitivity to serum and
8

proteases (136). Opa proteins are subject to both phase and antigenic variation (31).
As many as 12 (91,131) complete structural Opa genes exist in a single strain. All
genes are transcribed in full, and a single organism may independently and
spontaneously switch between states of expression and non-expression controlled at the
translational level (31). This alteration of expression and non-expression is known as
phase variation. Phase variation is dependent upon a region of the structural genes
located between the AUG initiation codon and the codons for the mature functional
protein (91). This region encodes the hydrophobic core of the signal peptide and is
comprised of identical repeating units of the pentamer CTCTT (31). The number of
repeats, ranging from 7 to 27 (91), places the Opa protein codons in-frame or
out-of-frame with the ATG initiation codon (30,31,91). Phase variation is therefore
controlled by changes in the number of CTCTT repeats of the signal peptide (31). The
rate of phase variation was estimated at 1x10 ^ to 1x10^/cell/generation (16,31,91).
Murphy et al. (91), suggested that stuttering or slippage of the RNA polymerase during
transcription of the signal peptide may result in an mRNA being translated that
normally would be out-of-frame. Slipped-strand mispairing during DNA replication
and unequal cross-over among coding regions of the signal peptide (91) were also
suggested to contribute to this high frequency of change by generating insertions or
deletions of CTCTT units (31,91)
Antigenic variation of Opa proteins is controlled by 4 short hypervariable (HV)
regions and 1 semivariable (SV) region found in the conserved framework of Opa
genes (91). These short HV regions are hydrophilic, surface exposed sections of the
9

protein located between conserved membrane bound sections. HV regions vary in
length and have almost no sequence homology (31). Intragenic reassortment and
recombination of HV regions may give rise to new HV sequences thereby adding to
antigenic variation (31,91). Evidence for this has been demonstrated by Connell et al.
(31), who identified identical copies of HV sequences in different combinations in
distinct Opa genes cloned from different sections of the genome.
In vitro experiments performed by Viiji et al. (142), showed transparent colonies
survived neutrophil attack while opaque colonies were killed. This suggested that
transparent colonies would be selected in actual gonococcal infection. However,
opaque colonies were more often recovered than transparent colonies from patients
with complicated gonococcal infection (133), while transparent colonies were isolated
from patients with localized, uncomplicated infections (20,133). These data suggested
that establishment of infection was dependent upon Opa proteins (11,30,133).
Therefore, Opa proteins may initiate infection by attaching to epithelial cells, thereby
facilitating invasion into those cells (30).
Rmp:
The reduction modifiable protein (Rmp) is a 30kDa protein first described by
McDade and Johnston in 1980 (85). Judd used '"l-peptide mapping to show that Rmp
is partially surface exposed and has conserved structure and molecular mass between
strains (69). Rmp was closely associated with For, as shown by immunoprecipitation
experiments (69). Rmp forms a heteropolymer with For (69,138) in a ratio of 3 Rmp
molecules to 1 For (73). Structural conservation, together with surface-exposure,
10

appeared to make Rmp an inviting vaccine candidate. However, in 1986 Rice et al.
(108), demonstrated that, in vitro, binding of anti-Rmp antibodies blocked insertion of
the membrane attack complex (MAC) of activated complement. These observations
were confirmed, in vivo, by Plummer et at. (101), in 1993. By inoculating human
volunteers, Plummer showed that anti-Rmp antibodies blocked deposition of MAC on
gonococcal membranes increasing susceptibility to reinfection.
Lipooligosaccharide:
Lipooligosaccharide (LOS) of N. gonorrhoeae, which comprises 1 % to 3 % of dry
cell weight (87), has similar structure to lipopolysaccharide (LPS) of other gram
negative bacteria, except it generally lacks the repeating "O" antigen (78,87).
Antigenic variation of LOS occurs at a rate of 1x10"^ per cell per generation (121) and
is independent of selective pressures (120). A given strain may produce between 1 and
6 physically distinct LOS molecules by changing the basic carbohydrate core structure
(78,87). Schneider et al. (119), showed that LOS variation occurred in vivo, and
resulted in a mimicry of human cell surfaces. It appears that the first 4 saccharide
residues at the N-terminus of the oligosaccharide structure were identical to a human
cell membrane glycosphingolipid known as paragloboside (78). Human paragloboside
is sialylated by cellular sialyltransferases and donation of sialic acid by cytidine
5'-monophospho-N-acetylneuraminic acid (CMP-NANA) (41). N. gonorrhoeae
expressed an endogenous sialyltransferase which uses CMP-NANA as a donor to
sialylate the lactosamine moiety of its LOS (5,41,78). Sialylation of LOS has been
associated with an increase in serum resistance and was recently correlated with
11

symptoms of infection (119). Sialylation may in^iede the immune response in a variety
of ways. Addition of sialic acid may mask LOS epitopes (30) normally recognized by
antibodies of gonorrhea patients (4,45). Sialylated LOS may also block antibodies
directed toward adjacent epitopes. For example. Frangipane et al. (41), showed that
LOS modified in this way blocked binding of bactericidal IgM and may also have
inhibited the deposition of C3b thereby interfering with both classical and alternative
complement pathways.
Sialylation is not the only modification of gonococcal LOS. Schneider et al. (119),
showed that the lactosamine moiety of LOS was also capable of being galactosylated.
Galactosylation of LOS covers CMP-NANA receptors preventing sialylation. This
observation implies the existence of, in vivo, competition between sialylation and
galactosylation of the lactosamine moiety of LOS (119).
LOS of N. gonorrhoeae is cytotoxic to fallopian tube cells (48). LOS was shown to
attach to cilia of fallopian tube epithelial and to be incorporated into those cells via
vesicle-like structures (32). LOS mediated the loss of ciliary activity and induced
sloughing of ciliated cells (32), thereby making it a significant pathogenic component
of the OM.
Capsule:
The existence of a capsule in N. gonorrhoeae was suggested by the gonococcal
production of polyphosphate (141), which may form a protective layer on the exterior
of some bacteria. However, polyphosphate may serve other functions, such as energy
storage, maintaining intracellular phosphate levels, or in DNA uptake (141). A
12

gonococcal capsule was first reported by Deacon in 1959 (34). Since then, the
existence of a gonococcal capsule has been an ongoing controversy. "Some hold that
it does possess a capsule, some question its existence, and some flatly deny that this
organism has a capsule" (Israli,1921) (60). In 1977 James et al. (64), examined 14
methods routinely used to identify capsules. Of these, India-ink wet mounts produced
the most consistent positive results for displaying gonococcal capsules (64). However,
N. gonorrhoeae capsule production was inconsistent (110) and expression was lost
during in vitro cultivation (54,110). In 1995, Tinsley et al. (141), produced Neisseria
mutants by insertionally inactivating the gene for polyphosphate kinase, an enzyme
used to synthesize polyphosphate, in N. gonorrhoeae, and N. meningitidis- These
mutants showed an increased sensitivity to serum killing and increased lysis upon
cessation of growth when compared to controls. The relationship between lack of
polyphosphate, and increased serum sensitivity and increased lysis was not determined.
Until the function of gonococcal polyphosphate is determined, the existence of a
gonococcal capsule will remain controversial.
IgA Protease:
Pathogenic Neisseria strains have an immunoglobulin class A (IgA) protease that
allows the organism to evade bactericidal IgA responses. Nonpathogenic Neisseria do
not have an IgA protease (90).
IgA is the major immunoglobulin of mucosal immunity in humans (90). The IgA
class of immunoglobulins is composed of 2 subclasses, IgA-1 and IgA-2 (13). IgA-1
comprises 93% of this immunoglobulin class leaving 7% for IgA-2 (13). The
13

subclasses differ in primary structure and arrangement of interchain disulfide bonds
causing IgA-1 and lgA-2 to differ in functional activities (13). Mucosal IgA exists as a
dimer with a secretory (S) segment and a joining (J) segment linking two IgA
molecules by their FC region (13). In the presence of lysozyme, mucosal IgA has
antibacterial activity directed mostly against gram negative organisms (13). This
bactericidal activity is thought to function by IgA binding organisms thereby preventing
them from attaching to epithelial surfaces (13). IgA aggregates were shown to activate
the alternative complement pathway also contributing to their antibacterial activity (13).
Extracellular IgA-1 protease of N. gonorrhoeae attacks prolyl-threonyl peptide
bonds located at the hinge region of the immunoglobulin's heavy chains (100) releasing
the FAB fragments of the IgA-1 mucosal dimer (90). IgA-2 contains a short deletion
containing the prolyly-threonyl peptide bonds making it resistant to the IgA protease
(100). Since 93% of all IgA is IgA-1, a protease of this specificity may be capable of
inactivating a major portion of IgA's antimicrobial activity. Furthermore, release of
actively binding FAB fragments impairs IgA's agglutination activity and may block
binding of intact antibodies (90).
Proteins in the 44,000 Dalton Range:
Recently, it has become apparent that there are at least 4 surface-exposed proteins, as
well as several other non-exposed proteins in the 44,000 Dalton (44kDa) range of N.
gonorrhoeae. The majority of these '44kDa proteins are not characterized. The
44kDa proteins were first reported in 1981 by Swanson (134), who described a surfaceradiolabled protein with an approximate mass of 44kDa that could be
14

immunoprecipitated from whole cells (134). Zak et al. (149), then reported a weakly
immunogenic 44kDa protein expressed in vivo that reacted with sera from 4 of 24
gonorrhea patients. In 1985, Chen et al. (27), demonstrated the presence of 8
lipoproteins in the outer membrane of N. gonorrhoeae. One, having an approximate
mass of 47kDa, was associated with the Multiple Transferable Resistance phenotype
(Mtr^). In 1989, Hill et al. (56), described a surface exposed "44kDa protein that
associated with peptidoglycan. Based on ^H-benzylpenicillin binding, this protein may
be penicillin binding protein 3 (PBP-3).
Genes were cloned for several of these 44kDa proteins. Porcella (103), cloned and
sequenced the genes for two 44kDa proteins. One non-exposed 44kDa protein was the
gonococcal homologue of Escherichia coli elongation factor Tu (EFTu). This invariant
protein was the dominant protein in periplasmic extracts (74). The other may be
surface-exposed and appeared to be lipoamide dehydrogenase (74). Hagman et al.
(51), cloned and sequenced the gene encoding a protein associated with the Mtr^
phenotype. Subsequently, they insertionally inactivated both the structural gene and a
regulatory gene. This structural gene, mtrC, encodes MtrC, a protein that shared
greater than 50% homology with E. coli AcrA and EnvC, and Pseudomonas
aeruginosa MexA (51). MtrC was invariant, surface-exposed (69), and involved in a
gonococcal hydrophobic efflux pump mechanism. Invariant expression and surfaceexposure make the MtrC protein an inviting vaccine candidate.
Recombinant Epitope Vaccine:
Considerable effort has been dedicated to develop a vaccine for the prevention of
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gonorrhea. Vaccine studies used fixed whole cells (130), or major OM components
such as Por (102,147) and pili (67) as immunogens. Vaccination with these
immunogens resulted in limited immunity to homologous strains, but offered no
immunity to heterologous strains. Strain-specific immunity may be attributed to the
immunological characteristics of the vaccination immunogens. For example, whole cell
immunogens presumably elicit antibody to the most immunogenic protein sequences on
the gonococcal OM. In clinical studies, Zak et al. (149) showed a large percentage of
antibody generated to gonococcal whole cells react with major OM components such as
Por, pili, and Opa. However, the antigenic determinants on Por (73,147), pili
(20,49,128), and Opa (31,91), differed between strains. Furthermore, Zak and
colleagues showed that antigenic determinants of pili and Opa changed during the
course of infection. The rate of change for both pili (130) and Opa (16,31,91) was
later determined to be 1x10"' per cell, per generation.
The fact that antibody was generated to antigenically variable sequences of exposed
proteins during the natural course of infection, indicated that these variable sequences
were immunogenically dominant to conserved sequences of exposed proteins.
Therefore, a vaccine using Por, pili, or Opa as immunogens, will not provide immunity
to all gonococcal strains, unless invariant sequences, common to all Por variants, pili
variants, or Opa variants are found. These invariant, immunorecessive sequences are
thought to exist in the conserved framework of gonococcal OM proteins.
The use of Por, pili, or Opa proteins in immunizations is unlikely. Por vaccines
were complicated by antibody reactive to Rmp (46,101,147), and antibody specific for
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For may be blocked from binding when gonococcal LOS is sialylated (75). A recent
study by Robinson et al. (112), confirmed the existence of conserved pilin sequences,
but could not confirm the surface-exposure of those sequences. A vaccine using Opa
proteins was never developed, probably due to the existence of at least 11 phase and
antigenically variable Opa genes (31,91,131) in the gonococcal genome.
The failure of vaccine studies underlines the ability of the gonococcus to evade
human immune system surveillance and stresses the need for a functional vaccine. The
above vaccines were complicated mostly by the variability of the immunogen used.
Most gonococcal OM proteins display significant antigenic variation, enabling the
bacteria to adapt to pressure from immune responses. Immunization problems have
then arisen from the finding that antigenically variable proteins were highly
immunogenic or immunodominant compared to the weak inmiimogenicity, or
immunorecessiveness of conserved, invariant proteins. Antibody generated to these
conserved, immunorecessive proteins may have bactericidal activity, thereby providing
protective immunity to all gonococcal strains.
In spite of the immune evasiveness of this bacteria, the possibility to develop a
frmctional vaccine remains. Plummer et al. (102), observed serovar-specific immunity
in prostitutes of Nairobi, Kenya. In addition, Buchanan et al. (22), reported decreased
recurrence of gonococcal salpingitis upon challenge with homologous strains. In fact,
some patients with gonococcal infections spontaneously recover without antibiotic
therapy (21,28).
A recombinant epitope vaccine is a developmental approach to vaccines, that should
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bypass problems seen with previous vaccines. Recombinant epitope vaccines employ
synthetic DNA encoding protein fragments of invariant, surface-exposed proteins.
Expression of the DNA produces immunogens which are used to stimulate antibody
generation to specific conserved sequences of gonococcal OM proteins. Antibody
generated to these conserved sequences may bind native protein thereby avoiding
problems of antibody production to immunodominant variable sequences and generation
of blocking antibodies.
This project focused on generating antibody to an invariant, immunorecessive
sequence from the 47kDa, gonococcal, Multiple Transferable Resistance C (MtrC)
membrane protein of Neisseria gonorrhoeae. The protein sequence of the MtrC
protein was applied to a system to select a sequence most probable to be a B cell
epitope, and to evaluate that sequence as a recombinant epitope vaccine candidate. The
selection/evaluation system used computer algorithms (Kyte-Doolittle, MacVector) (81)
that chose the 13 amino acid sequence, "'ISKQEYDAAVTAK"', most likely to
function as a B cell antigenic determinant, based on surface-probability, hydrophilicity,
flexibility, and antigenicity data. This sequence, termed MtrC antigenic peptide 1
(MtrC API), was too small to stimulate antibody by itself. To overcome this problem,
recombinant DNA and synthetic peptide techniques were used to create MtrC API
immunogens with greater immunogenicity than the native MtrC API sequence.
Hypotheses:

The major hypothesis of this project was that recombinant DNA and
synthetic peptide techniques can make it possible to generate antibody
to an invariant, immunorecessive sequence (MtrC API) by increasing
the immunogenicity of that sequence.
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The secondary hypothesis of this project was that the
MtrC API sequence would be useful in a recombinant epitope
vaccine for the prevention of gonorrhea.
To test these hypotheses, the following Specific Aims were investigated:
1. Production of a recombinant ftision protein between MtrC API and
maltose binding protein using recombinant DNA technology and the
pMAL-CRl plasmid.
2. Generation of a MtrC API-specific antiserum using the recombinant fusion
protein and synthetic MtrC API sequence contained in the multiple
antigenic peptide systems (MAPS) immunogens.
3. Evaluation of antibody binding to native MtrC by Western blotting and
radioimmunoprecipitation.
4. Functional characterization of MtrC API-specific polyclonal antiserum by efflux
inhibition and bactericidal assays.
MATERIALS AND METHODS
Materials and Reagents:
Restriction endonucleases Xhol, Xbal, EcoRl, T4 DNA ligase, and T4 kinase were
obtained from New England BioLabs (NEB, Beverly, MA) and used according to
manufacturer's specifications. The pMAL-CRl Vector System was also obtained from
NEB. This kit contained all needed reagents for recovery and purification of maltose
binding protein fusions. Escherichia coli, DH5a competent cells were acquired from
Gibco BRL ( Gaithersburg, MD). Plasmid was isolated using a Qiagen plasmid
preparation kit (Qiagen, Chatsworth, Ca). DNA was prepared using a Gene Clean
DNA purification kit (BiolOl, Lajolla, Ca). Calf intestine alkaline phosphatase (CIP)
and Quick Spin G-25 sephadex colunms were obtained from Boehringer Mannhein
Biochemicals (Indianapolis, IN). N. gonorrhoeae bacterial strain FA19 (FA 19) was
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available from the laboratory of Dr. Ralph Judd, University of Montana, Missoula,
MT. N. gonorrhoeae MtrC hyperexpression strain KH8 (KH8) and MtrC deletion
mutant KH13 (KH13) were generous gifts from the laboratory of Dr. Bill Shafer,
Emory University (Atlanta, GA). Radioactive iodine (Nal^^) was obtained from New
England Nuclear (Boston, MA). Biotin and strepavidin were acquired from Pierce,
(Rockford, IL) and used according to manufacturer specifications. Enhanced
chemiluminescence (ECL) reagents were acquired from Amersham (Arlington Heights,
IL). Multiwell (24 well) tissue culture plates used in the bacterial microassay, were
obtained from Falcon (Lincoln Park, NJ). Microtiter immunoassay plates were
acquired from Dynatech Laboratories, Inc (Chantilly, VA). Ampicillin, ethidium
bromide, molecular mass markers, goat anti-rabbit horseradish peroxidase conjugate
(GAR-HP), goat anti-rabbit alkaline phosphatase (GAR-AP), and isopropyIthio-p-Dgalactoside (IPTG) were obtained from Sigma chemical company (St. Louis, MO).
All other chemicals were reagent grade or better. Immimoblotting was performed
using Millipor (Bedford, MA) Immobilon polyvinylidene difluoride (PVDF) and a
Bio-Rad Trans-Blot Cell (Hercules, CA).
Gonococcal growth, harvesting, SDS-PAGE, Western blotting:
Strains FA19, KH8, And KH13 were grown at Bô.S^C in a 5% CO; atmosphere on
clear typing medium as described by Swanson (135). Colonies were selected for Opa
negative, pili negative phenotype and passed daily. Cells were harvested, solubilized,
separated by sodium dodecyl sulfate polyacrylamide gel electtophoresis (SDS-PAGE)
as described by Judd (71). Separated proteins were electrophoretically transferred onto
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PVDF using a Trans-Blot Cell as described by Judd (71). Immunoblotting was
performed in degassed 20mM phosphate buffer, Ph 8.0 for 16hr at 0.6A. PVDF blots
were blocked in 0.05% Tween-20 in Dulbeco's phosphate buffered saline (dPBS) for
Ihr at room temperature.
Genetic Fusion of the MtrC Antigenic Peptide to Maltose Binding Protein:
A synthetic oligonucleotide encoding the amino acid sequence
"'ISKQEYDAAVTAK^^^ from the 47,000 Dalton (47kDa) MtrC protein of strain
FA19, was genetically fused to E. coli malE gene encoding maltose binding protein
(MBP) using the pMAL-CRl plasmid (NEB). The MtrC amino acid sequence was
selected for its surface exposure and antigenicity, as predicted by computer algorithms
(Kyte-Doolittle, McVector), and was referred to as the MtrC antigenic peptide 1 (MtrC
API). The oligonucleotide encoding MtrC API was synthesized by the Murdock
Molecular Biology Facility (MMBF) (Missoula, MT). The oligonucleotide was
synthesized with EcoRl and Xbal restriction endonuclease sites to insure proper
orientation and in-frame insertion into the pMAL-CRl vector system and a TAA stop
codon to prevent expression of the lacZa gene (Figure 1). The oligonucleotide was
also engineered with a Xhol restriction endonuclease site upstream from the stop codon
to allow further additions to the fusion protein.
The synthetic oligonucleotides encoding MtrC API (OJfig) were digested with
restriction enzymes EcoRl and Xbal at 37°C for Ihr. The digested oligomers were
then annealed to 0.5fig of pMAL-CRl predigested with EcoRl, Xbal and ligated with
4 units T4 DNA ligase overnight at 18°C in a total volume of 100/il. The EcoRl, and
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Xbal restriction sites allowed for positioning of the oligonucleotide in the same
translational reading frame as the malE gene under the control of the tac promoter.
The pMAL-CRl vector was transformed into 200/il competent E. coli DH5a cells.
Cells were heat shocking by incubation at 42°C for 60sec then cooled in an ice bath
followed by incubation for 30min at 3TC in Luria-Bertani broth (LB). After
incubation, cells were plated on LB media containing 100/tg/ml ampicillin (LB Amp).
Each transformed colony was then transferred with sterile tooth picks to LB Amp
plates containing lOO^g/ml ampicillin, 0. ImM IPTG, and 80/ig/ml Xgal and incubated
overnight at 37°C. On this medium, transformed cells harboring the pMAL-CRl
plasmid with a synthetic DNA insert produced white colonies due to insertional
inactivation of p-galactosidase encoded by lacZa. In contrast, transformed cells
receiving pMAL-CRl plasmid without the insert produced blue colonies due to the
enzymatic activity of p-galactosidase on Xgal. Transformants were then regrown in
LB Amp broth at 37°C to an optical density of 0.5 at 600 nanometers (nm)
(ODgoonm^O 5). Plasmid DNA was recovered and purified by Qiagen plasmid
preparation. Recovered plasmid DNA was sequenced at MMBF to confirm correct
orientation of the insert into the pMAL-CRl vector. The resultant construct, pMALCRl-MtrC API, was then used to produce a MBP/MtrC API fusion protein.
Fusion Protein Production:
The MBP/MtrC API fusion protein was produced as described in Short Protocols
in Molecular Biology (111). A 10ml overnight culture of E. coli DH5a/pMAL-CRlMtrC API cells was used to inoculate a 1 liter volume of LB Amp broth. This culture
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was grown to an OD6oomn=0.4- At this point, IPTG was added to a final concentration
of 0.3mM and the culture was incubated for an additional 2hr at 37°C. The cells were
then collected by centrifugation at 4,000xg for 30min and the supernatant was
discarded. The cell pellets were resuspended in SOml lysis buffer and sonicated for
5min. Sodium chloride was added to the lysed cell suspension to a concentration of
0.5M and the suspension was centrifuged at 12,(XX)xg for 30min to clarify the extract.
The clarified crude extract was retained.
Fusion Protein Isolation:
The MBP/MtrC API fusion protein was affinity purified with amylose resin
included in the pMAL-CRl vector kit. Fusion protein was isolated according to the
manufacturer's specifications with the modification that amylose columns were replaced
by amylose batch purification. The following procedure was performed at 4°C.
Hydrated amylose (15ml) was added to a 50ml conical centrifuge tube and allowed to
settle. The amylose was washed with 3 column volumes of 0.25% Tween-20 column
buffer by gentle resuspension and centrifugation at 50xg for 5min. The crude extract
was applied to the amylose batch. The batch was gently resuspended and allowed to
settle. Crude extract supernatant was removed and the amylose was washed with 3
column volumes of 0.25 % Tween-20 column buffer and 5 volumes column buffer
without Tween-20. All washings were performed by gentle resuspension followed by
centrifugation at 50xg for 5min. Twice, 25ml elution buffer containing lOmM maltose
was applied to the amylose batch which was gently resuspended and centrifuged at
50xg for 5min. Void volume was recovered by centrifugation of the amylose in quick
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spin tubes at lOOOxg for lOmin. Eluates containing the fusion protein were pooled and
dialyzed overnight against distilled water at 4°C to remove maltose. Protein
concentration was estimated by absorption at 280^.
Generation of Polyclonal Antiserum:
Polyclonal rabbit antiserum was produced against MtrC API. Two New Zealand
white rabbits were used for this procedure. Sera were collected from both rabbits
before the initial injection and used as control normal rabbit antiserum throughout this
experiment. Purified MBP/MtrC API fusion protein (Img) in 1ml Freund's complete
adjuvant was used as the primary immunogen. The inoculum (0.5ml) was injected
subcutaneously at the axilla and inguinal sites. Rabbits were boosted every 2 weeks in
an immunization procedure essentially described by Porcella (104). Secondary
immunizations were performed using synthetic MtrC API sequence contained in MAPS
immunogens. Rabbits were boosted with MAPS (Img) subcutaneously at the axilla and
inguinal sites in Freund's incomplete adjuvant (FIC) followed by intramuscularly in
FlC and intravenously in dPBS. The MAPS used in this protocol was eight synthetic
MtrC API peptides fused to a polylysine backbone (Figure 4). MAPS was used to
specifically boost antibody production to MtrC API.
Enzyme-Linked Inunimosorbent Assay:
An enzyme-linked immunosorbent assay (ELISA), was performed using 96 well
Immulon plates. Synthetic MtrC API sequence contained in MAPS immunogens
(7/ig/ml in phosphate buffered saline, solution A; PBS-A) was used to coat plates
(100^1/well) by incubation for 18hr at 4°C. Wells were then blocked with 1.0%
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bovine serum albumin (BSA), 0.01 % NaNj in PBS-A (200^1/well) for 18hr at 4°C, to
prevent nonspecific binding of antibody. Adhered MAPS was incubated with
antiserum generated to FA19 OM preparations, fixed FA19 whole cells, or MtrC API,
as the positive control, for 18hr at 4°C. Antiserum was added at a starting dilution of 1
to 100 in blocking buffer (100/il) and 2 fold serially diluted to a final dilution of
1/51,200. After incubation, wells were washed six times with 0.05% Tween-20 in
dPBS. Wells were incubated with goat anti-rabbit alkaline phosphatase (1 to 1000 in
blocking buffer) for 2hr at 37"C. Wells were again washed six times with 0.05 %
Tween-20 in dPBS. The substrate, p-nitro phenyl phosphate in diethanolamine (1 tab
in 10ml) was added (150^1) to each well and plates were incubated at room temperature
for 30min. Optical density of the wells were read by a Vmax ELISA plate reader
under control of the Softmax program at wavelength 405^.
Radioimmimoprecipitation:
Radioimmunoprecipitation (RIP) was performed as described by Judd (69). KH8
was used in this experiment. Rabbit polyclonal MtrC API antiserum was used for this
experiment. Rabbit polyclonal FA19 whole cell antiserum was used as a positive
control. Normal rabbit antiserum was used as a negative control. All antisera were
absorbed with E. coli DH5a cell lysates prior to use. E. coli DH5a cells were grown
in 10ml LB broth to an OD^oonm^l O- The culture was then sonicated for 5xlmin and
pelleted. The pellet, resuspended in 2ml dPBS, was used in a 1 to 1 ratio for antisera
absorption.
Strains were grown to an ODgoonm=1-36 and suspended in 100^1 4°C dPBS. Nal'^
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(4/il, 25/ici//til) was added to each reaction tube and incubated on ice for 30min.
Reaction mixtures were transferred to iced microfuge tubes predried with iodogen and
incubated on ice for 30min. Reaction mixtures were then transferred to clean tubes to
stop the reaction and washed three times in 4°C dPBS. Antisera (100/il) were added to
reaction mixtures containing KH8 and incubated on ice for 20min. Reaction mixtures
were pelleted, resuspended in 200jttl 1% Zwittergent 3-14, and incubated at 37°C for
Ihr. Reaction mixtures were again pelleted, and 200/il of the supernatant was
removed. Protein-A Sepharose 4B-CL (40/il, SOmg/ml) was added to the
supematants which were incubated at room temperature for lOmin. Protein-A
Sepharose beads were then pelleted, and washed twice with 1 % Zwittergent 3-14 in
cold dPBS. Pellets were resuspended in absolute ethanol, pelleted, and evaporated to
dryness in a boiling water bath. Pellets were solubilized in 50^1 SDS-solubilizing
solution and boiled for 15min. Solubilized samples were separated by SDS-PAGE.
Autoradiography was then performed.
Biotm Surface Labeling, Immunoprecipitation:
Biotin labeling of surface proteins was performed by manufacturer's specifications
(Pierce, Rockford, IL). KH8 was used in this experiment. Cells were harvested in
dPBS to an OD6oonn,=0.68. Biotin reaction solution (1^1 of 50mg/ml in DMSO, diluted
1/20 with water) was added to three 1.5ml samples which were then incubated on ice
for 2min. After incubation, biotin labeled cells were washed twice with 50mM trisHCl (SO/il), Ph 7.5 to remove excess unbound biotin.
Cell samples were resuspended in 100/tl antisera absorbed with E. coli DH5a cell
26

lysates. MtrC API-specific rabbit antiserum, whole cell antiserum (positive control),
and normal rabbit antiserum (negative control) were used for this experiment. Cell
samples were washed twice with ice cold dPBS and resuspended in Zwittergent 3-14
(200^1). Samples were vortexed, incubated at 37°C for Ihr with shaking, and
centrifuged at TOOOxg for 5min. Protein A sepharose 4B-CL, (SOfil at 50mg/ml in
dPBS), was added to 200/tl of supernatant and incubated for lOmin at room
temperature. This reaction mixture was centrifuged at TOOOxg for 2min, washed twice
with Zwittergent 3-14, and solubilized by addition of SDS-solubilizing solution with
boiling.
Solubilized samples were separated on a 15 % polyacrylamide SDS-PAGE gel and
blotted onto a PVDF membrane as previously described (56). The PVDF membrane
was blocked in TTBS buffer containing 3 % skim milk, washed three times with TTBS,
and incubated with 10/il strepavidin-horseradish peroxidase diluted in 50ml TTBS (Ihr
at room temperature). Unbound strepavidin was removed by washing with 60°C TTBS
for 15min, followed by two 15min washes with 3TC TTBS. Washed PVDF was
incubated for Imin in an equal volume mixture of luminol reagents 1 and 2 supplied by
the manufacturer (Amersham). The blot was then covered by plastic wrapping and
exposed to hyper-film MP for 15, 30, 45, and 60sec.
Serum Killii^ Assays
Bactericidal Microassay:
The Bactericidal Microassay was performed as described by Pettit (97); a
modification of Schneider and Griffiss (122). Antisera used in this assay were
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sterilized by passage through 0.22/im filters and heated to 56®C for 30min to inactivate
intrinsic complement. Heat inactivated (HI) MtrC API-specific antiserum and HI
normal rabbit antiserum supplemented with 10% human complement (C) were used in
this assay with KH8. Controls included HI MtrC API-specific antiserum and HI
normal rabbit antiserum without C, and C in the absence of antibody. A 2 fold serial
dilution (1/4 - 1/4096) of antisera (2(X) /til) in gonococcal typing broth (200jnl) was
carried out in multiwell tissue culture plates. Equal volumes of typing broth containing
3x10" colony forming units (CFU)/ml were added to each well. Plates were incubated
for 45min at 37"C. After incubation, wells were overlayed with 300/il molten agar
equilibrated to 52°C. Plates were then incubated for 16hr in 5% CO; at 37°C.
Bactericidal titer was defined as "the reciprocal of the greatest dilution of antisera
producing 100% killing of test strain" (97).
Bactericidal Microassay/Dilution Plate Combined Assay:
The bactericidal microassay/dilution plate combined assay was performed as
described by Eisenstein (37). Bactericidal microassay was performed as described
above through the 45min incubation at 37"C. At this point, 10/tl was removed from
each well and spread on gonococcal typing medium. Medium was incubated for 24hr
in 5% CO; at 37°C. After incubation, CPUs were counted for each antiserum
treatment and compared with controls. Bactericidal titer was defined as "the reciprocal
of the greatest dilution of antisera producing equal to, or greater than 80% reduction in
CPUs when compared to control wells" (37). Controls included those of the
bactericidal microassay.
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Disk Diffusion Assay:
The disk diffusion assay (10) was performed to determine if MtrC API-specific
antiserum would block the function of the hydrophobic efflux pump. FA19, KH8, and
KH13, were used in this assay. Antisera used in this assay were incubated for 30min
at 56°C to inactivate complement and filter sterilized by passage through 0.22/tm
filters. Equal volumes (10ml) of gonococcal typing medium supplemented with 0.5%,
and 0.25% HI MtrC API-specific antiserum, or 0.5%, and 0.25% HI normal rabbit
antiserum were applied to glass petri dishes. Sterile dPBS was added to insure volume
consistencies between media plates with different concentrations of antiserum. Liquid
culture (l(X)/il of a 5x10' CFU/ml) of each strain was evenly spread on media plates
which were incubated for 30min at 37°C to allow the culture to absorb into the
medium. Absorbent disks were aseptically transferred to plates then treated with 20/il
100, 10, and Img/ml Triton X-1(X). dPBS was used as a negative control. Plates were
incubated in 5% CO;, at 37®C for 18hr. After incubation, areas of zones of inhibition
were measured and compared between different antisera treatments.
Broth Culture Efflux Inhibition Assay:
The broth culture efflux inhibition assay was performed to determine the ability of
MtrC API-specific antiserum to block the function of the hydrophobic efflux pump.
This assay was performed at 37°C. Antisera were sterilized by passage through
0.22^m filters, and incubated at 56°C for 30min to inactivate complement. FA19 or
KH8, ODgoonn,=1.0, were used to inoculate prewarmed gonococcal typing broth (1 to
20 dilution) supplemented with 0.5% HI MtrC API-specific antiserum, 0.5% HI
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normal rabbit antiserum, or 0.5% dPBS. The culture mixtures (100/tl) were added to a
96 well microtiter plate; lanes A-H, columns 2-12. Equal volumes (100/il) of the same
culture mixture containing inhibitory concentrations of Triton X-100 (6400/tg) were
added to lanes A-H, columns 1-2. A 2-fold serial dilution was performed in lanes AH, columns 2-12 with the excess volume at the end of the dilution being dicarded. The
microtiter plate was placed on a Vmax microtiter plate reader operated by the Softmax
program. The program was set to record absorbance values at 650^ every 43sec for
4hr with intermittent shaking.
RESULTS
Genetic Fusion of MtrC API and MBP in pMALrCRl:
A synthetic oligonucleotide encoding the protein sequence "^SKQEYDAAVTAK"^
(MtrC API) was cloned into the pMAL-CRl vector resulting in pMAL-CRl-MtrC
API (Figure 1). This oligonucleotide was fused to Escherichia coli malE gene
encoding maltose binding protein (MBP), and under the control of the isopropylthio-pD-galactoside (IPTG)-inducible tac promoter.
Production and Isolation of Fusion Protein:
The pMAL-CRl-MtrC API construct was transformed into E. coli DH5a cells.
Transformed cells containing the oligonucleotide produced white colonies due to
insertional inactivation of the lacZa peptide. Sequencing of plasmid recovered from
DH5a/pMAL-CRl/MtrC API cells confirmed the oligonucleotide to be in the same
translational reading frame as malE (data not shown). DH5a/pMAL-CRl-MtrC API
cells were induced with IPTG, for overexpression of the fusion
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Figure 1. The genetic fusion of MtrC API to Escherichia coli maltose binding protein
(MBP) encoded by the malE gene under the control of the isopropyl-thio-galactoside
inducible tac promoter in the pMAL-CRl vector system (NEB). MtrC API insert was
designed with an internal restriction endonuclease site for the possible addition of more
peptide sequences and a stop codon to prevent expression of lacZa, resulting in
selective production of the MBP/MtrC API fusion protein.
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protein, and harvested. The MBP/MtrC API fusion was isolated by affinity
chromatography using amylose resin. Fusion protein was eluted from amylose resin
using lOmM maltose. The eluted fusion protein having an apparent mass of 44kDa,
was identified in a Coomassie Brilliant blue-stained 15% SDS-PAGE gel (Figure 2).
This mass was consistent with the estimated combined mass of MBP (42kDA) and
MtrC API (l.SkDa) of 43.5kDa. The identity of the fusion protein was confirmed by
Western blot analysis using antiserum specific for MBP
(Figure 3).
Generation of MtrC API-Specific Antiserum:
Purified MBP/MtrC API fusion protein was used as the primary immunogen in
rabbits for the generation of polyclonal antiserum. Boosting was performed with
synthetic MtrC API sequence contained in MAPS immunogens (Figure 4). The fusion
protein made an excellent immunogen, but elicited antibody to the carrier protein,
MBP, as well as MtrC API. The polyclonal antiserum generated in this manner
strongly recognized the MtrC protein in both FA19 and KH8 (Figure 5). The
MBP/MtrC API fusion protein migrated at approximately 44kDa, close to the native
MtrC protein of 47kDa (Figure 5). Since the polyclonal antiserum recognized both
components of the fusion protein, i.e. MBP and MtrC API, it was shown that antibody
specific for MBP did not recognize protein in N. gonorrhoeae (Figure 3). Primary
immunization with MBP/MtrC API fusion protein followed by secondary
immunization with MAPS resulted in highly reactive polyclonal antiserum specific for
MtrC API.
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Figure 2. Separation of lysates of Neisseria gonorrhoeae strain FA19 and strain KH8
whole cells, Escherichia coli DH5a whole cells, and MBP/MtrC API fusion protein in
a 15% SDS-PAGE gel stained with Coomassie Brilliant blue. Control (DH5a) and
pMAL-CRl-MtrC API containing (DH5a/pMAL-CRl-MtrC API) E. coli are next to
N. gonorrhoeae MtrC hyperexpression strain KH8 and parent strain FA19, followed by
purified MBP/MtrC API fusion protein. Molecular mass markers (MW) were from
the BIO-RAD low molecular weight kit and are expressed in thousands of Daltons (K).
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Figure 3. Separation of lysates of Neisseria gonorrhoeae and Escherichia coli whole
cells and MBP/MtrC API fusion protein in a 15% SDS-PAGE gel, immunoblotted on
PVDF and probed with antiserum reactive to maltose binding protein. Control E. coli
cells (XL1blue) and E. coli cells containing the pMAL-CRl-MtrC API plasmid
(DH5a/pMAL-CRl-MtrC API) are next to N. gonorrhoeae parent strain, FA19. Next
to FA19 is purified MBP/MtrC API fusion protein prepared without a protease
inhibitor and two samples of MBP/MtrC API fusion protein prepared with the addition
of sodium azide to the recovery procedure. Molecular mass of the MBP/MtrC API
fusion protein (44) is expressed in thousands of Daltons.
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Figure 5. Western blot showing separation of whole cell lysates of Neisseria
gonorrhoeae and Escherichia coli in a 15% SDS-PAGE gel, blotted on PVDF and
probed with MtrC API-specific antiserum. Control (DH5a) and pMAL-CRl-MtrC
API containing E. coli are next to N. gonorrhoeae MtrC hyperexpression strain KH8,
and two samples of N. gonorrhoeae parent strain FA19, followed by purified
MBP/MtrC API fusion protein. Molecular mass (44) of the MBP/MtrC API fusion
protein is expressed in thousands of Daltons.
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Enzyme-Linked Inunimosorbent Assay:
Antiserum generated against FA 19 whole cells and FA 19 outer membrane (OM)
preparations were tested for reactivity to MtrC API by enzyme-linked immunosorbent
assay (ELISA). MtrC API sequence contained in MAPS immunogens was allowed to
adhere to multiwell plates and incubated with dilutions of antisera FA19 whole cells,
FA19 OM preparations (primary antisera), MtrC API-specific antiserum (positive
control), and normal rabbit antiserum (negative control). The plates were then
incubated with alkaline phosphatase conjugated goat anti-rabbit IgG (secondary
antiserum). Addition of substrate to alkaline phosphatase produced a color change
indicating successful binding of the primary antiserum. Color intensity was directly
related to the degree of recognition of MAPS by the antisera. Color intensities were
compared by absorbance values at 450^. Figure 6 A, shows recognition of the MAPS
immunogen by MtrC API-specific antiserum (HI, gold) confirming both enhanced
reactivity to MtrC API and high antibody titers. Figure 6 B, shows MAPS recognition
by normal rabbit antiserum (NRS, blue), and antisera generated to FA19 whole cells
(Anti-WC, red), and FA19 OM preparations (Anti-OM, green). Both whole cellspecific and OM-specific antisera recognized MtrC API contained in MAPS, higher
than did normal rabbit antiserum. Although this does not confirm surface-exposure of
the MtrC API sequence, it does indicate the association of MtrC API with the
gonococcal OM.
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Figure 6. Recognition of synthetic MtrC API sequence contained in MAPS by
antisera generated against Neisseria gonorrhoeae parent strain FA19 whole cells, FA19
outer membrane (OM) preparations, MtrC API-specific antiserum, and normal rabbit
antiserum. Degree of recognition was measured by optical density (OD) using an
enzyme-linked immunosorbent assay (ELISA). A) OD vj antibody titer for MtrC APIspecific antiserum (HI, gold), normal rabbit antiserum (NRS, blue), FA19 whole cellspecific antiserum (Anti-WC, red), and antiserum generated to FA19 OM preparations
(Anti-OM, green), showing enhanced recognition of MAPS by MtrC API-specific
antiserum. B) OD vs antibody titer for 2-fold serial dilutions (1/50 - 1/6400) of normal
rabbit antiserum, FA19 whole cell-specific antiserum, and FA19 OM-specific
antiserum. Both FA 19 and OM-specific antisera showed significant recognition of
MAPS suggesting an association between MtrC API and the gonococcal outer
membrane.
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Radioimmunoprecipitation and Biotin Labeled Immimoprecipitation:
Radioimmunoprecipitation (RIP) experiments used radioactive iodine (Nal^^) to
surface label exposed OM proteins of KH8 cells. Radiolabled cells were incubated
with MtrC API-specific antiserum and lysed with Zwittergent 3-14. Bound MtrC
API-specific antiserum was immunoprecipitated by incubation with Protein-A
Sepharose, solubilized in sodium dodecyl sulfate (SDS), and separated in a 15% SDSPAGE gel. Controls included incubation with antiserum generated against FA19 whole
cells (positive control), and incubation with normal rabbit antiserum (negative control).
A comparable technique involving chemically labeling exposed OM proteins with biotin
was also used. Controls for this technique included incubation without antiserum
(negative control), incubation with FA19 whole cell-specific antiserum (positive
control), and incubation with normal rabbit antiserum (negative control).
Both RIP (Figure 7) and biotin labeling followed by immunoprecipitation (Figure 8)
displayed nonspecific immunoprecipitation of proteins such as porin (Por) and
reduction modifiable protein (Rmp) in addition to MtrC.
Nonspecific immunoprecipitation of proteins may be partially attributed to
incomplete solubilization of the gonococcal membrane. To maintain antibody-protein
interactions, a non-denaturing detergent, Zwittergent 3-14 was used. Under these mild
conditions, MtrC API-specific antiserum appeared to precipitate fragments of
membrane containing several proteins in addition to MtrC.
Furthermore, protein-A sepharose beads precipitated several proteins in the
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Figure 7. Radioimmimoprecipitation of proteins from Neisseria gonorrhoeae strain
KH8. KH8 whole cells were surface-labeled with Nal^", incubated with antisera, and
inimunoprecipitated with protein-A sepharose. Immunoprecipitated proteins were
separated in a 15 % SDS-PAGE gel, blotted to PVDF, and incubated with Hyperfilm
MD for 10 days at -70°C. This autoradiogram shows proteins bound by FA19 whole
cell-specific antiserum and immunoprecipitated with protein-A sepharose next to
proteins bound and immunoprecipitated using normal rabbit antiserum, followed by
proteins bound and immunoprecipitated using MtrC API-specific antiserum.
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Figure 8.. Neisseria gonorrhoeae strain KH8 whole cells were surface-labeled with
biotin, incubated with antisera, and immunoprecipitated with protein-A sepharose.
Immunoprecipitated proteins were separated in a 15 % SDS-PAGE gel and blotted to
PVDF. Horseradish-peroxidase conjugated strep-avidin was bound to biotin on
chemically labeled, blotted proteins which were incubated for Imin in equal volummes
luminol reagents 1 and 2. This autoradiogram shows protein immunoprecipitated using
FA19 whole cell-specific antiserum (positive control) next to proteins
immunoprecipitated using normal rabbit antiserum (negative control), followed by
proteins immunoprecipitated using MtrC API-specific antiserum. Protein-A sepharose
(negative control) nonspecifically immunoprecipitated protein in the absence of
antibody.
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absence of antisera (Figure 8). These beads are charged and porous and may trap
proteins nonspecifically. Incubation of protein-A sepharose beads in blocking buffers
such as dPBS Tween, bovine serum albumin (BSA), and skim milk, prior to
immunoprecipitation, had no effect on nonspecific protein precipitation.
Serum Killing Assay
Bactericidal Microassay:
To determine if MtrC API-specific antiserum possessed bactericidal activity in
presence of human complement, the bactericidal microassay was performed. 2-fold
serial dilutions of complement heat inactivated (HI) MtrC API-specific antiserum with
10% human complement (C) (1/4 -1/4096) was performed in a multiwell tissue culture
plate containing 60(K) CFU/well KH8. The bactericidal microassay employed visual
confirmation of the bactericidal titer by complete clearing of wells. Controls included
incubation of KH8 with HI MtrC API-specific antiserum without C, HI normal rabbit
antiserum with C, HI normal rabbit antiserum without C, and C alone.
MtrC API-specific antiserum with C did not yield a bactericidal titer, however,
partial clearing was seen to a titer of 32 (Figure 9). Normal rabbit antiserum with C,
and C without antibody also displayed partial clearing to a titer of 32, suggesting
clearing was non-antibody mediated human complement activity. However, visual
discernment suggested a greater degree of clearing in wells incubated with MtrC APIspecific antiserum and C than in wells incubated with normal rabbit antiserum and C,
or wells incubated with C without antibody.
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Figure 9. Bactericidal microassay. Neisseria gonorrhoeae strain KH8 was incubated
with two fold serial dilutions (1/4 - 1/4096) of sterile antisera, heat inactivated for
complement and reconstituted with 10% human complement (C). MtrC API-specific
antiserum with C, normal rabbit antiserum with C, and C alone, were diluted two
fold and incubated overnight with 6000 CPUs KH8. Bactericidal titers were defined as
"the reciprocal of the greatest dilution of antibody resulting in 100% killing of the test
strain (97)." Bactericidal titers were not reached. However, all antisera displayed
partial clearing to an antibody titer of 32. Furthermore, MtrC API-specific antiserum
with C showed a significantly higher degree of killing than control antisera.
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Bactericidal microassay/dilution plate combined assay:
To determine the degree of killing, the bactericidal microassay/dilution plate
combined assay was performed. The bactericidal microassay was performed as
described in Materials and Methods with the addition of a 10/il sample from each well
being spread on gonococcal typing media. Controls for this assay were the same used
in the bactericidal microassay.
Bactericidal titer was not reached. However, in comparison with controls, a
greater reduction in CPUs was seen in samples incubated with MtrC API-specific
antiserum and C than in samples incubated with normal rabbit antiserum and C, or
samples incubated with C without antibody. Figure 10 shows percent killing of KH8
cells by MtrC API-specific antiserum and normal rabbit antiserum with and without
C, and C without antibody. MtrC API-specific antiserum with C showed greater
killing of KH8 cells than did normal rabbit antiserum with C in every antiserum
dilution tested.
At the highest concentration of antiserum (25 %), MtrC API-specific antiserum with
C killed 28% more of the test strain than did normal rabbit antisera with C. At the
same antisera dilution, C in the absence of antibody showed 60% less killing of the
test strain than did MtrC API-specific antiserum, suggesting moderate bactericidal
activity of MtrC API-specific antiserum.
Disk Diffusion Assay:
The gonococcal hydrophobic efflux pump allows for increased survival in the
presence of hydrophobic agents such as Triton X-100 (51). Disk diffusion assays
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Figure 10. To determine the degree of killing seen in the bactericidal microassay, the
combined dilution plate/bactericidal microassay was performed using Neisseria
gonorrhoeae strain KH8. The combined assay was performed as the bactericidal
microassay with the exception that instead of agar overlays, a lOjul sample was
removed from each well and plated on gonococcal typing media. Bactericidal titers
were defined as "the reciprocal of the greatest dilution of antisera resulting in equal
to/or greater than 80% reduction in colony forming units when compared to controls"
(37). Bactericidal titers were not definitively reached with any antisera tested.
However, 78% killing of the test strain was seen at a titer of 8 in samples incubated
with HI MtrC API-specific antiserum and C (HI

4- C,gold).

At this titer, samples

incubated with HI normal rabbit antisera and C (NRS + C, blue) displayed 55%
killing, whereas samples incubated with C without antibody (C alone, green)
displayed less then 7 % killing of the test strain. HI MtrC API-specific antiserum (HI,
pink) and HI normal rabbit antiserum (NRS, purple) not supplemented with C, did not
show significant killing of KH8 at any antibody titer.
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were performed to determine whether MtrC API-specific antiserum would block the
gonococcal efflux pump, increasing gonococcal susceptibility to Triton X-100.
FA19, KH8, and KH13, were incubated on gonococcal typing media supplemented
with 0.25% and 0.5% MtrC API-specific antiserum, and 0.25% and 0.5% normal
rabbit antiserum, and normal gonococcal typing medium. Absorbent disks containing
20jLil of different concentrations of Triton X-100 were then applied to the medium.
Medium was incubated in 5 % CO; at 37°C for 16hr. Areas of zones of inhibition were
compared between antisera treatments.
In initial results, areas of zones of inhibition varied significantly between duplicate
samples possibly due to slight volume differences in media. After volume differences
were resolved, variation in areas of zones of inhibition lessened but still varied in
repeat experiments (Figure 11). This may be attributed to the absorbent properties of
the disks. Disks absorbed moisture from the media prior to the application of Triton
X-100 which resulted in immediate diffusion from the disk and dilution of Triton X100. To overcome this, media plates were incubated for a variety of different times to
allow drying of the media. Addition of drying time to this procedure did not abolish
variation in zones of inhibition.
Figure 11 shows areas of zones of inhibition of FA19 averaged over repeated
experiments. A bar graph was used to compare areas of zones of inhibition (mm^) and
antiserum treatment for 3 different concentrations of hydrophobic agent, Triton X-100 .
Results displayed slightly larger areas of zones of inhibition for media supplemented
with MtrC API-specific antiserum compared to controls,
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Figure 11. Disk diffusion assay. Neisseria gonorrhoea strain FA19 was grown on
gonococcal typing medium supplemented with sterile, complement heat inactivated (HI)
normal rabbit antiserum (0.25% and 0.5%), or HI MtrC API-specific antiserum
(0.25% and 0.5%), and overlayed with absorbent disks containing 20/tl of Img/ml
(red), lOmg/ml (green), or lOOmg/ml (blue) Triton X-100. Area of zones of inhibition
were compared between antisera treatment and Triton X-100 concentration. Variation
from the mean of areas of zones of inhibition are shown as error bars.
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which indicated possible efflux pump inhibition. However, variation between
experiments disallowed conclusive determination of gonococcal efflux pump inhibition.
Results from KH8 and KH13 are not shown. Strain KH8, which displayed
increased resistance to hydrophobic agents due to hyperexpression of the MtrC protein,
did not show measurable zones inhibition with any concentration of Triton X-100 used.
In contrast, strain KH13, which displayed increased susceptibility to hydrophobic
agents due to deletion of the MtrC protein, showed zones of inhibition too large to be
measured with all concentrations of Triton X-100.
Broth Culture Efflux Pump Inhibition Assay:
The broth culture efflux pimip inhibition assay overcame the problems encountered
in the disk diffusion assay. In a 96 well ELISA plate, FA19 or KH8 were used to
inoculate gonococcal typing broth supplemented with either 0.5% MtrC API-specific
antiserum, normal rabbit antiserum, or dPBS. An inhibitory concentration of Triton X100 (6400jttg/well) was applied to the first well and diluted 2-fold to a noninhibitory
concentration of 6pig/well. Cells were grown with absorbance values taken every
43sec. Growth curves were then compared between antisera and dPBS treatments.
Figure 12 shows growth curves of KH8 incubated with MtrC API-specific
antiserum, normal rabbit antiserum, and dPBS. Significant differences in growth were
not displayed between KH8 incubated with either serum treatment or dPBS. Increasing
the antisera concentration to 1.0% also did not result in discernable differences in
growth. Growth curves generated with FA 19 (data not shown) also did not show
significant differences between antisera treatments.
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Figure 12. Broth culture efflux inhibition assay. Neisseria gonorrhoeae strain KH8
was grown in 96 multiwell plate in gonococcal typing broth supplemented with sterile,
complement inactivated (HI) antisera and decreasing concentrations of Triton X-100
(6400/ig/well to 6/ig/well). A Vmax ELISA plate reader, operated by the Softmax
program, recorded ODggq values every 43sec for 4hr. Growth curves for different
antisera treatments were plotted. Control (KH8) is next to KH8 + 0.5% HI MtrC
API-specific antiserum and KH8 + 0.5% HI normal rabbit antiserum, followed by
KH8 + 0.5% dPBS. No significant differences were displayed between growth curves
generated with the different antisera treatments. Increasing the antiserum to 1.0% also
showed no differences in growth. Growth curves generated using FA19 (data not
shown), at 0.5% and 1.0% antisera showed no significant differences between antisera
treatments.
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Figure 13. Diagrammatic representation of the gonococcal hydrophobic efflux pump
encoded by the mtrRCDE operon. The protein products of this operon show significant
sequence similarity to the protein products of Escherichia coli opérons acrRAE and
envRCD and Pseudomonas aeruginosa operon mexABoprK (51), known to encode
efflux pump mechanisms (93). The MtrC protein appears to bridge the periplasmic
space, associated with MtrD on the inner membrane, and MtrE on the outer membrane.
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Figure 14. Plots of computer algorithms (Kyte-Doolittle, MacVector) of the MtrC
protein sequence (GenBank accession number Z25796). These plots show predicted
hydrophilicity, surface probability, flexibility, and antigenicity index based on amino
acid sequence.
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F^iire 15. An expansion of the computer algorithm plot (Kyte-Doolittle, MacVector)
of the MtrC protein showing the amino acid sequence of MtrC API,
""ISKQEYDAAVTAK"'. The amino acid sequence, "SKQEY", is predicted to be the
most hydrophilic and have the highest surface probability of the MtrC API sequence.
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DISCUSSION
Neisseria gonorrhoeae, the causative agent of gonorrhea, is one of the most
reported diseases in the United States, with up to a million new cases per year (6,20).
One of the factors contributing to the spread of N. gonorrhoeae is the lack of an
effective vaccine. Whole cell and pilin vaccines showed specificity for homologous
strains only (124). Presumably, this is because, in N. gonorrhoeae, variable, exposed
sequences of surface proteins, tend to be immunodominant. In comparison, invariant,
exposed sequences of surface proteins are immunorecessive (116). Thus, antibody is
generated to variable sequences rather than invariant sequences resulting in an immune
response that does not recognize a heterologous gonococcal strain.
The major hypothesis tested in this study was that recombinant DNA and synthetic
peptide techniques would make it possible to immunize with invariant, apparently
immunorecessive sequences in the absence of immunodominant, variable sequences.
Protective antibody could then be generated against otherwise immunorecessive
sequences. This approach to vaccine development should generate immune responses
that protect against a wide spectrum of gonococcal strains.
To test the hypothesis, a system was used to select and evaluate invariant
gonococcal OM sequences as possible vaccine candidates. This selection/evaluation
system employed computer algorithms to identify an amino acid sequence from an
invariant protein, which was most likely to be antigenic and surface-exposed. An
oligonucleotide encoding the computer selected sequence was synthesized and fused to
the Escherichia coli malE gene which encodes maltose binding protein (MBP). The
68

genetic fusion was constructed in the plasmid pMAL-CRl. The pMAL-CRl plasmid
produced a MBP/gonococcal antigenic sequence fusion protein which was used in
conjunction with synthetic peptide to generate polyclonal antiserum. The resultant
antiserum was studied to determine the potential usefulness of the gonococcal sequence
in a recombinant vaccine.
The project focused on the 47,000 Dalton Multiple Transferrable Resistance C
(MtrC) protein of N. gonorrhoeae. The MtrC protein was a potential vaccine candidate
because iodination experiments showed it was surface-exposed, and immunological and
genetic studies confirmed that it was universally expressed in an invariant form among
gonococcal strains (69). The MtrC protein is encoded by the mtrC gene which is part
of the mtrRCDE operon. This operon encodes the constituents of a hydrophobic efflux
pump (51). The MtrC protein sequence (51) showed 50% similarity to Escherichia coli
AcrA (83) and EnvC (79) and Pseudomonas aeruginosa MexA; all structural proteins
involved in hydrophobic efflux pumps (93) (Figure 13).
Computer algorithms chose amino acid residues 119-131 of the MtrC protein as a
putative surface-exposed sequence based on hydrophilicity, surface probability,
antigenicity, and flexibility (Figure 14 and 15) (29,36,42,81). This sequence,
"'ISKQEYDAAVTAK"', was the first sequence investigated from the MtrC protein
and thus termed the MtrC antigenic peptide 1 (MtrC API). Subsequent MtrC protein
sequences will be designated MtrC AP2, MtrC AP3, etc.

MtrC API was

expected to function as a B cell epitope, which would stimulate the production of
specific antibody. MtrC API however, was too small to elicit a strong immune
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response and appeared not to contain a T cell epitope needed for B cell activation. To
provide T cell epitopes and sufficient molecular mass, the DNA encoding MtrC API
was ligated to the 3' end of the E. coli MBP gene, malE (Figure 1). This resulted in
the expression of MtrC API in a fusion protein (MBP/MtrC API), which had sufficient
size, complexity, and presumably, an adequate number of T cell epitopes to produce
antisera to MtrC API.
The pMAL-CRl vector system was used to produce the MBP/MtrC API fusion
protein. The pMAL-CRl vector lacked the malE signal sequence resulting in
cytoplasmic hyper-expression of the fusion protein under control of the strong tac
promoter. The tac promoter is a fusion of the trp and lac operon promoters resulting
in a lactose inducible promoter with high affinity for the E. coli DNA dependent RNA
polymerase, which therefore allowed for rigorous gene expression. The pMAL-CRl
plasmid also contained the lacP gene encoding the lac repressor which limited
transcription. High mRNA production and therefore translation was induced by the
addition of the lactose analog isopropyl-thio- p-D-galactoside which inactivated lacP.
The pMAL-CRl vector contained an E. coli malE-lacZa gene fusion, a factor Xa
cleavage site downstream of malE, and an ampicillin resistance gene. A multiple
cloning site located between the malE-lacZa gene fusion allowed ligation of an
oligonucleotide encoding an epitope in-frame with malE. Insertion of the
oligonucleotide disrupted p-galactosidase activity encoded by the lacZa gene. The
plasmid containing an oligonucleotide was transformed into an a fragment
complementing host cell. Transformants were screened on LB-Xgal-ampicillin media.
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Ampicillin insured selective growth of transformed cells due to the ampicillin resistance
gene encoded by pMAL-CRl. Xgal provides an easy selection of transformants based
on colony color differences.
An oligonucleotide encoding MtrC API was engineered to contain EcoRl and Xbal
restriction endonuclease sites, an internal Xhol restriction endonuclease site, and a
TAG stop codon (Figure 1). EcoRl and Xbal allowed for in-frame, and directional
ligation of the oligonucleotide in the multiple cloning site between malE and lacZa,
resulting in a plasmid construct pMAL-CRl-MtrC API (Figure 1). The Xhol site was
engineered directly downstream from the MtrC API-encoding sequence. In this
location, the Xhol and EcoRl restriction endonuclease sites would allow for ligation of
additional sequences, such as MtrC AP2, 3, etc, to MtrC API without disrupting the
original sequence. The TAG stop codon followed Xhol and prevented expression of
the lacZa open reading frame, thereby insuring selective production of the MBP/MtrC
API fusion protein. Fusion protein could then be isolated by affinity chromatography
using amylose resin. This process exploited MBP's differential affinities for amylose,
a polymer of glucose, and maltose, a glucose dimer. Since MBP has higher affinity for
maltose, than amylose, the MBP/MtrC API fusion protein could be eluted from
amylose batches with lOmM maltose. Separation of MtrC API from MBP could be
accomplished by the addition of factor Xa. Factor Xa recognizes a cleavage site
encoded by pMAL-CRl directly downstream from MBP. Separated MBP may then be
removed from MtrC API by repeating the fusion protein isolation procedure.
Thus, pMAL-CRl allowed for high level cytoplasmic expression of a MBP/MtrC
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API fusion protein, and a means to separate MtrC API from MBP, providing an
inexpensive way to amplify and isolate a gonococcal sequence of interest.
The plasmid pMAL-CRl-MtrC API was sequenced to confirm the MtrC APIencoding oligomer was in the proper orientation and in-frame with malE. Cells
containing the pMAL-CRl-MtrC API plasmid were used to produce MBP/MtrC API
fusion protein. Cells were induced with IPTG, necessary for fusion protein expression,
and harvested in lysis buffer. The MBP/MtrC API fusion protein was purified from
cell lysates by affinity chromatography using amylose resin. Eluted fusion protein
having an apparent molecular mass of 44kDa, was identified in a Coomassie Brilliant
blue-stained 15% SDS-PAGE gel (Figure 2). This mass was consistent with the
estimated combined mass of MBP (42kDa) and the MtrC API (1.5kDa) of 43.5kDa.
The identity of the MBP/MtrC API fusion protein was confirmed by Western blot
analysis using antiserum specific for MBP (Figure 3).
The MBP/MtrC API fusion protein was used to generate rabbit polyclonal
antiserum. Presumably, MBP provided molecular mass, complexity, and an adequate
number of T cell epitopes necessary to activate B cells for the production of antiserum
specific for MtrC API. However, since MBP contained its own B cell epitopes, it was
itself immunogenic. To direct antiserum production specifically toward MtrC API
only the primary immunization contained the MBP/MtrC API fusion protein, while
boosting injections were performed using synthetic MtrC API in the multiple antigenic
peptide system (MAPS)
(Figure 4)(40,105).

The MAPS immunogen used in this procedure was composed of 8 synthetic MtrC
API peptide sequences linked to a polylysine backbone (Figure 4). The MAPS
technology is probably too expensive for large scale clinical immunizations and MAPS
immunogens may not be good for primary immunizations depending upon the
antigenicity of the sequence used. However, when used as a secondary immunogen to
the MBP/MtrC API fusion protein, MAPS immunogens provided sufficient mass to
stimulate antibody production to the MtrC API sequence. Moreover, any identified B
cell or T cell epitope can be quickly and efficiently synthesized in this manner. It has
also been suggested that MAPS could be synthesized with heterologous sequences,
thereby providing both B cell and T cell epitopes on the same immunogen (105).
The MtrC API-specific polyclonal antiserum generated in this fashion strongly
recognized complete gonococcal MtrC protein in Western blots (Figure 5).
These results confirmed the hypothesis that recombinant DNA techniques and
synthetic peptide made it possible to immunize with an invariant, immunorecessive
sequence. The fusion protein made an excellent primary immunogen. Secondary
immunizations using MAPS, specified antibody production to the immunorecessive
sequence. The successful production of antiserum using this procedure showed it is
possible to quickly and easily make polyclonal antiserum to invariant immunoreccessive
sequences of gonococcal OM proteins.
The successful production of polyclonal antiserum to an invariant, immunorecessive
sequence led to the secondary hypothesis that MtrC API would be useful in a
recombinant epitope vaccine. To be useful, MtrC API must be located in the surface73

exposed region of the MtrC protein and antiserum specific for MtrC API must inhibit
bacterial survival possibly by blocking the function of the hydrophobic efflux pump, or
through bactericidal activity.
An essential aspect of the secondary hypothesis was that MtrC API was a surfaceexposed portion of the intact MtrC protein as predicted by computer algorithms (Figure
14 and 15). To insure that MtrC API was associated with the gonococcal OM, the
MtrC API sequence contained in MAPS immunogens was used in an enzyme-linked
immunosorbent assay (ELISA) experiment. The MAPS immunogen was adhered to 96
well Inmiulon ELISA plates, and incubated with decreasing concentrations of antisera
generated to both FA19, fixed whole cells and OM preparations (Figure 6). Both
antisera strongly recognized the MAPS immunogens. Although this did not indicate
surface-exposure of MtrC API, it did indicate association of MtrC API with the
gonococcal OM.
To determine if this region was exposed, antiserum to MtrC API was used in
immunoprecipitation experiments. First, Radioimmunoprecipitation (RIP) experiments
used radioactive iodine (Nal'^) to surface label exposed outer membrane proteins of N.
gonorrhoeae (69). Radiolabeled cells were incubated with MtrC API-specific
polyclonal antiserum followed by immunoprecipitation of bound MtrC API-specific
antiserum by incubation with Protein-A Sepharose. Additionally, exposed OM proteins
were chemically labeled with biotin followed by incubation and immunoprecipitation
with MtrC API-specific antiserum.
Both techniques demonstrated precipitation of MtrC protein, but nonspecific
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precipitation of other proteins was also observed (Figure 7 and 8). Porin (Por) and
reduction-modifiable protein (Rmp) were the primary proteins precipitated
nonspecifically with the MtrC API antiserum. This was not surprising since Por
comprises up to 60% (73) of the protein in the OM and is complexed with Rmp. Por
appeared to interact nonspecifically with the MtrC API antiserum in Western blots
(Figure 5), probably accounting for Por and Rmp being immimoprecipitated. MtrC
API-specific antiserum was generated in rabbits. Since nonspecific
immunoprecipitation of Por was also seen in proteins immunoprecipitated with normal
rabbit antiserum, it is possible that nonspecific immunoprecipitation of Por is due to
cross-reactive antibody in rabbit serum generated to the OM of another gram negative
organism.
Incomplete solubilization of the gonococcal outer membrane by non-denaturing
detergents may also have contributed to the precipitation of proteins other than MtrC.
Outer membrane proteins of Gram-negative bacteria are extremely hydrophobic and
difficult to solubilize with detergents. Adding to the problem is the fact that MtrC
protein is a lipoprotein that is particularly difficult to completely solubilize in
detergents other than the denaturing detergent sodium dodecyl sulfate (SDS). Since
SDS disrupts antibody-protein interaction, it was not feasible to use SDS in
immunoprecipitations. A non-denaturing detergent, Zwittergent 3-14 was used to
maintain antibody-antigen interaction in RIP experiments. Under these milder
conditions, MtrC API-specific antiserum appeared to precipitate fragments of intact
membrane containing several other proteins (eg. Por and Rmp) in addition to MtrC
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(Figure 8).
In addition to incomplete solubilization, protein-A sepharose beads precipitated
several proteins in the absence of antibody (Figure 8). These beads are charged and
porous, and can trap proteins nonspecifically. Steps were taken to block nonspecific
interaction, such as incubation with blocking buffers. Blocking buffers such as, dPBS
Tween-20, bovine serum albumin (BSA), and skim milk had no effect on nonspecific
protein precipitation. Thus radioimmimoprecipitation and biotin labeling followed by
immunoprecipitation, did not conclusively demonstrate surface exposure of MtrC API.
The bactericidal microassay (97,122) was performed to determine whether MtrC
API-specific antiserum was bactericidal in the presence of human complement. Equal
numbers of gonococcal cells (KH8) were incubated with 2 fold serial dilutions of
human complement and either MtrC API-specific antiserum or normal rabbit
antiserum, and human complement in the absence of antibody. Although bactericidal
titers were not be reached, more clearing was seen in sanq>les incubated with MtrC
API-specific antiserum and human complement than in controls.
To determine the amount of serum killing that may have occurred, the bactericidal
microassay/dilution plate combined assay was performed (37). Results indicated a
greater reduction in colony forming units in samples incubated with MtrC API-specific
antiserum and human complement than in samples incubated with normal rabbit
antiserum and human complement, or samples incubated with human complement in
the absence of antibody (Figure 10). Although bactericidal titers by the definition
above were not reached, these results may indicate moderate bactericidal function of
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the MtrC API-specific antiserum.
Low bactericidal activity may be explained by location of expressed MtrC protein
in the test strain's OM. MtrC protein has been shown to be a minor protein in the
gonococcal membrane (51). Since it takes two IgG immunoglobulins in close
proximity to bind and activate complement, MtrC API-specific antiserum bound to the
MtrC API epitope may not have been close enough to activate complement.
Growth inhibition assays were used to see if the MtrC API-specific antiserum
would block efflux pump function. The efflux pump enhances the survival of
gonococci in the presence of hydrophobic antibiotics and detergents (51). MtrC APIspecific antiserum may bind the MtrC protein and inhibit the function of the
hydrophobic efflux pump. Gonococcal growth inhibition in the presence of MtrC APIspecific antiserum and a hydrophobic agent such as Triton X-100, would also indicate
surface exposure of MtrC API.
The ability of MtrC API-specific antiserum to block efflux pump function was
investigated using the disk diffusion assay (10). FA19, KH8, and KH13, were grown
on plates containing MtrC API-specific antiserum or normal rabbit antiserum.
Absorbent disks containing Triton X-100 were then applied. Areas of zones of
inhibition were measured and compared between the different antisera treatments
(Figure 11).
Initial results showed zones of inhibition to be slightly larger for plates receiving
MtrC API-specific antiserum indicating possible efflux pump inhibition. However,
areas of zones of inhibition varied significantly in duplicate samples presumably due to
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variations in the volume of gonococcal media.
After volume variations had been eliminated, differences in areas of zones of
inhibition between antisera treatment lessened but still varied significantly between
repeat experiments. This may be attributed to the absorbent properties of the disks.
For example, to insure sterility and consistent volume, hydrophobic agent Triton X-100
was applied to the absorbent disks only after the disks were transferred to the media.
This allowed the disks to absorb moisture from the media which resulted in diffusion
variation and dilution of Triton X-100 immediately upon its application. Absorbent
disks with a larger volume capacity along with various time scales for media incubation
before disk transfer (to allow media to dry) were also tested. These procedures did not
resolve the problems. Consequently, results were inconclusive as to the surface
exposure of MtrC API as well as the ability of MtrC API-specific antiserum to inhibit
efflux pump function.
To overcome the problems seen with the disk diffusion assay, the broth culture
efflux pump inhibition assay was performed using FA 19 and KH8. Broth cultures
were treated with either MtrC API-specific antiserum, normal rabbit antiserum, or no
antiserum and incubated wiûi decreasing concentrations of Triton X-100. Cultures
were allowed to grow with absorbance values taken every 43sec for 4hr. Growth
curves were determined from these values and compared between antisera treatments.
Figure 12 shows computer generated (Softmax) growth curves of KH8 incubated
with 0.5% MtrC API-specific antiserum, 0.5% normal rabbit antiserum, and 0.5%
dPBS. Very little differences were displayed between growth of this organism
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incubated with MtrC API-specific antiserum, and either normal rabbit antiserum or
dPBS. Increasing the antisera treatment to 1.0% also did not result in significant
growth differences. These results suggest that MtrC API-specific antiserum does not
inhibit the function of the gonococcal hydrophobic efflux pump.
In summary, the major hypothesis of this project was confirmed. Recombinant
DNA techniques and synthetic peptide made it possible to immunize with an invariant,
immunorecessive sequence in the absence of an immunodominant, variable sequence.
Confirmation of this hypothesis was accomplished by employing a system to select and
evaluate invariant gonococcal OM sequences as possible vaccine candidates. This
system used computer algorithms that predicted MtrC API to be a surface-exposed,
antigenic sequence of the invariant, gonococcal OM protein, MtrC. Due to its high
level of cytoplasmic expression and easy product purification techniques, the pMALCRl vector system was used to genetically Aised MtrC API to a carrier protein, MBP,
resulting in the MBP/MtrC API fusion protein. The fusion protein was used in an
immunization protocol with synthetic MAPS immunogens to generate a highly reactive
polyclonal antiserum specific for MtrC API. The fusion protein made an excellent
primary immunogen eliciting antibody to the carrier protein, MBP, as well as MtrC
API. Synthetic MAPS immunogens were then used to specifically boost antibody
production to MtrC API. The successful production of antibody in this fashion
provides the technique to quickly and easily acquire antiserum to specific sequences of
interest on the gonococcal OM. The antiserum may then be characterized to evaluate
the sequence of interest for possible use in a antigonococcal vaccine.

The secondary hypothesis tested was that MtrC API would be useful in a
recombinant epitope vaccine. To test this hypothesis, MtrC API-specific antiserum
was used in experiments to confirm surface-exposure of MtrC API, and determine the
ability of MtrC API-specific antiserum to block the gonococcal efflux pump, and to
kill the gonococcus in the presence of human complement.
Collectively, the results fi"om the above experiments produced equivocal results.
Due to incomplete solubilization and nonspecific immunoprecipitations, both RIP and
biotin labeling followed by immimoprecipitation experiments were unable to confirm
whether MtrC API is surface-exposed. The disk diffusion assay, used to determine the
ability of MtrC API-specific antiserum to block the gonococcal efflux pump, gave
highly variable results, but displayed a general trend toward gonococcal efflux pump
inhibition. However, the broth culture efflux inhibition assay was unable to confirm
this trend showing inability of the antiserum to block the gonococcal efflux pump. The
ability of MtrC API-specific antiserum to kill gonococci in the presence of human
complement was then investigated using serum killing assays. These assays displayed a
significantly higher percent killing of N. gonorrhoeae by MtrC API-specific antiserum
than control antisera. These results suggest that not only is MtrC API surfaceexposed, but antibody to MtrC API has bactericidal activity in high concentrations.
Results from surface-exposure, gonococcal efflux pump inhibition, and serum
killing experiments summarized above, suggest further hypotheses about MtrC API.
The first hypothesis is that MtrC API is not surface-exposed. MtrC API was
predicted by computer algorithms to be surface-exposed and antigenic. Most algorithm

programs of this type use amino acid sequence to predict hydrophilicity, antigenicity,
flexibility and secondary structure (B sheet, a helix, etc). The secondary structure is
then used to predict surface-exposure. Based on comparison with other efflux pump
proteins with which MtrC shares significant similarity, the MtrC protein is thought to
bridge the periplasm interacting with MtrD on the inner membrane, and MtrE on the
OM (Figure 13). This location would give MtrC significant surface area in which it
would interact with periplasmic contents. The surface of MtrC interacting with the
periplasm would most probably be hydrophilic. Therefore, computer algorithms may
have correctly predicted MtrC API to be located in an exposed region of the MtrC
protein. MtrC API may be exposed to the periplasm rather than the surface.
However, results fi-om serum killing assay suggest MtrC API is surface-exposed.
Furthermore, ELISA experiments performed using antisera generated to FA19 whole
cells and FA19 OM preparations suggest MtrC API is associated with the OM.
An alternative hypothesis from the results is that MtrC API is located in the
surface-exposed region of the MtrC protein, but is minimally accessible to interaction
with antibody. It is thought that the MtrC protein exists in a depression on the
gonococcal OM. The MtrC protein has been shown to be accessible by radioactive
iodine (69), and biotin (personal observation), but may have limited accessibility by
antibody. Both radioactive iodine and biotin are small molecules which may pass into
the depression that antibody, being ISOkDa, may be too large to access. In a
manuscript entitled '"The Canyon Hypothesis'', this phenomena has been seen in the
influenza virus and in rhinovirus 14 (115). It is thought that depressions, or canyons'
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on the surface protect proteins essential for host interactions, or virulence, from host
immune responses. MtrC API may be in the surface-exposed region of the MtrC
protein, but part or all of MtrC API may be inaccessible to the antigen binding region
of MtrC API-specific antibody by the walls of the canyon'.
The third hypothesis generated by the above results is that MtrC API is partially
surface-exposed and partially not surface-exposed. The computer algorithm shown in
Figures 14 and 15, predicted the amino acid sequence "SKQEY" of MtrC API
(ISKQEYDAAWTAK) to be the most likely to be surface-exposed. Again, MtrC is
thought to be a periplasmic efflux accessory protein bridging the cytoplasmic efflux
transporter (MtrD) to the OM protein MtrE (Figure 13). Therefore, it is possible that
the sequence "ISKQEY" of the MtrC API amino acid sequence, is exposed to the
surface with the remaining amino acids, "DAAVTAK", being associated with MtrE. If
this is the case, it may allow weak antibody recognition of the MtrC API sequence
which may support the moderate bactericidal activity seen in the serum killing assays.
Weak antibody binding may also account for the contradictory results displayed in
gonococcal efflux pump inhibition assays. As stated above, the disk diffusion assay
showed a general trend toward efflux pump inhibition by antiserum specific for MtrC
API. However, the broth culture efflux inhibition assay was unable to show efflux
pump inhibition by MtrC API-specific antiserum. The disk diffusion assay, which is
performed on solid medium, encompassed a mixed age population of bacteria.
Therefore, MtrC API-specific antibody bound to the MtrC API sequence may have
differential ability to block the function of the MtrC protein depending on changes in
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the bacterium due to age. In contrast, the broth culture efflux inhibition assay supports
a more consistent population of gonococci. The gonococcus was grown to mid-log
phase in gonococcal typing broth before in was introduced into the broth culture efflux
inhibition assay. Therefore, MtrC API-specific antibody bound weakly to the MtrC
API sequence of healthy, mid-log gonococci, may not block the fimction of the MtrC
protein.
The inconclusive and somewhat contradictory results stated above suggest MtrC
API may not be a good epitope to use in a recombinant epitope vaccine. However,
since the MtrC protein is invariant, conserved among gonococcal strains, surfaceexposed (69), and is involved in an efflux based resistance mechanism (51), it still
remains an inviting vaccine candidate. Other sequences will undoubtedly be identified
from the MtrC protein and applied to the system described above. However, a more
inviting protein may be MtrE. It is suggested that the MtrE protein exist in a ratio of 2
to 1 with the MtrC protein (Figure 13). Although it has not been sequenced, the MtrE
protein is thought to be the OM component of the hydrophobic efflux pump which
would allow for direct interaction with antibody of the host immune response. In this
location, MtrE may be crucial to the function of the efflux pump and antibody specific
for MtrE may have important bactericidal activity.
Many studies have focused on development of an antigonococcal vaccine. As stated
earlier, these vaccine studies centered on the use of killed whole cells, or whole cell
components such as pilin. Whole cell (102) and whole cell (67) component vaccines
displayed partial immunity to homologous strains only, mainly due to the extreme
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variability of presumed immunodominant, exposed gonococcal OM protein epitopes.
Therefore, it is hypothesized that invariant, immunorecessive epitopes of exposed,
proteins may elicit protective antibody.
Recombinant epitope vaccines provide the means to immunize with invariant,
immunorecessive epitopes, thereby bypassing problems with variable epitope
immunodominance. The ideal vector for a gonococcal recombinant epitope vaccine
would be nonpathogenic to the recipient, able to express a large number of foreign
proteins, and able to induce cellular, humoral, and mucosal immunity with long lasting
immune system memory.
Many viruses and bacteria, capable of expressing foreign protein antigens, are
being studied for use as recombinant vaccine vectors. For example, the mengo (1,2)
virus has a stable attenuated phenotype and does not integrate into the host's
chromosome. Recombinant mengo virus expressing lymphocyte choriomenigitis virus
(LCMV) nucleoprotein was shown to induce immunity in mice stimulating both
humoral and cellular immunity. Recombinant adenoviruses have induced antibody
production to hepatitis B virus (HBV) in dog (28), and hamsters (88), rabies in skunks
and foxes (26), human immunodeficiency virus (HIV) in dogs (92), and herpes simplex
virus (HSV) in mice (66). Recombinant vaccinia virus has induced immunity in mice
to rabies, and is being studied as a recombinant vaccine vector in immunizations with
HIV antigens (43). Attenuated poliovirus, used in the Sabin vaccine, was shown
capable of expressing foreign proteins in the VPl structural protein (107), and is
known to induce secretory as well as humoral antibody responses (44).
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Bacterial vectors include recombinant Yersinia enterocolitica used to immunize
mice to the cholera toxin B subunit (129). Escherichia coli was studied as a
recombinant vector for Shigella flexneri proteins (52). Possibly the best studied
recombinant bacterial vector for use in a vaccine belongs to Salmonella typhi.
Recombinant S. typhi was used in separate clinical studies expressing the "O" antigen
of Shigella sonnei (15), and Vibrio cholera (39). Although neither vaccine provided
immunity to all recipients, the results were encouraging for the use of Salmonella
species as bacterial vaccine vectors. It was shown that not only does S. typhi induce
humoral and cellular responses, S. typhi preferentially binds M cells (epithelial cells of
the Peyer's patches), thereby inducing mucosal immune responses as well (126).
In conclusion, a variety of recombinant vaccine vectors, both viral and bacterial,
have been characterized, and may prove useful in an antigonococcal recombinant
epitope vaccine. Although the epitope described in this project, MtrC API, may not be
ideal epitope to use in an antigonococcal vaccine, the system used to select and evaluate
MtrC API is advantageous. For instance, if the MtrC API epitope was deemed
beneficial to an antigonococcal vaccine, the DNA encoding MtrC API is retained in the
pMAL-CRl-MtrC API plasmid. The MtrC API-encoding DNA could then be excised
from pMAL-CRl-MtrC API and ligated into a suitable recombinant vector using the
existing restriction endonuclease sites. Therefore, the selection/evaluation system used
in this project, which employed recombinant DNA procedures and synthetic peptide
techniques, provided the needed technology to generate highly reactive antiserum to
invariant, immunorecessive sequences, the means to characterize those

immunorecessive sequences, and a way to retrieve the DNA encoding those
immunorecessive sequences.

86

BIBLIOGRAPHY
1. Altmeyer, R., M, Girard, S. Van-Der-Werf, V. Mimic, L. Seigneur, and M. F.
Saron. 1995. Attenuated Mengo Virus: A New Vector for Live Recombinant Vaccines.
J. Virol 69(5):3193-3196
2. Altmeyer, R., N. Escriou, M. Girard, A. Palmenberg, S. Van-Der-Werf. 1994.
Attenuated Mengo Virus as a Vector for Immunogenic Human Immunodeficiency Virus
Type 1 Glycoprotein 120. Proc. Natl. Acad. Sci. USA 91 (21):9775-9779
3. Amies, C. R. 1969. Sensitivity of Neisseria gonorrhoeae to Penicillin and Other
Antibiotics. Brit. Jr. Ven. Dis. 45:216-222
4. Apicella, M. A., M. A. Westerink, S. A. Morse, H. Schneider, P. A. Rice, and J.
M. GrifGss. 1986. Bactericidal antibody response of normal human serum to the
lipooligosaccharide of Neisseria gonorrhoeae. J. Infect. Dis. 153:520-526
5. Apicella, M. A., R. E. Mandrell, M. Shero, M. E. Wilson, etal. 1990.
Modification by Sialic Acid of Neisseria gonorrhoeae Lipooligosaccharide Epitope
Expression in Human Urethral Exudates: An Immunoelectrom Microscope Analysis. J.
Infect. Dis. 162:506-512
6. Aral, S. O. and etal.. 1991. Pelvic inflammatory disease: Research directions in
the 1990's. Sex. Trans. Diseases 18:46-64
7. Ashford, W. A., R. G. Golash, V. G. Hemming 1976. Penicillinase-Producing
Neisseria gonorrhoea. Lancet 2:657-658
8. Ault, K. A. 1993 Pelvic Inflammatory Disease. Current Diagnostic Criteria and
Treatment Guidelines. Postgrad. Med.
9. Barrera, O. B. and J. Swanson. 1984 Proteins LA and IB exhibit different
orientations in the outer membrane of Neisseria gonorrhoeae. Infect. Immun.
44:565-568
10. Bauer, A. W. ,et al. 1966. Antibiotic Susceptibility Testing by a Standardized
Single Disk Method. AM. J. Clin. Pathol. 45:493
11. Belland, R. J., T. Chen, J. Swanson, and S. H. Fischer. 1992. Human neutrophil
response to recombinant neisserial Opa proteins. Mol. Microbiol. 6:1729-1737
12. Belland, R. J., S. G. Morrison, P. van der Ley, and J. Swanson. 1989.
Expression and phase variation of gonococcal P.II genes in Escherichia coli involves
87

ribosomal frameshifting and slipped-strand mispairing. Mol. Microbiol 3:777-786
13. Benjamini, E., S. Leskowitz. 1991. Immunology : A Short Course. Second
Edition. New York, NY. Wiley and Sons Inc. 2:pg 54,61,76,140
14. Birkenmeyer, L. and A. S. Armstrong. 1992. Preliminary evaluation of the ligase
chain reaction for specific detection of Neisseria gonorrhoeae. J. Clin. Microbiol.
30:3089-3094
15. Black, R. E. M. M. Levine, M. L. Clements, et al. 1987. Prevention of
Shigellosis by a Salmonella typhi-Shigella sonnei Bivalent Vaccine. J. Infect. Dis.
155:1260-1265
16. Black, W. J., R. S. Schwalbe, I. Nachamkin, and J. G. Cannon. 1984.
Characterization of Neisseria gonorrhoeae Proteinll Phase Variation by Use of
Monoclonal Antibodies. Infect. Immun. 45:453-457
17. Blake, M. S. 1987. Pilin Variants in Experimental Gonorrhea. J. Exp. Med.
165:1344-1357
18. Blake, M. S., E. C. Gotschlich, and J. Swanson. 1981. Effect of proteolytic
enzymes on the outer membrane proteins of Neisseria gonorrhoeae. Infect. Immun.
34:212-222
19. Boslego, J., R. Chung, J. Sadoff, et al. 1984. Efficacy Trial of a Purified
Gonococcal Pilus Vaccine. IN: Program and Abstracts of the 24Th Interscience
Conference on Antimicrobial Agents and Chemotherapy, Washington DC. Amer. Soc.
Microb.
20. Britigan, B. E., M. S. Cohen, and P. F. Sparling. 1985. Gocococcal infection: a
model of molecular pathogenesis. N. Engl. Jr. Med. 312:1683-1694
21. Buchanan, T. M. and J. F. Hildebrandt. 1981. Antigen-specific serotyping of
Neisseria gonorrhoeae: characterization based on the principal outer membrane protein.
Infect. Immun. 32:985-994
22. Buchanan, T. M., D. A. Eschenbach, J. S. Knapp, and K. K. Holmes. 1980.
Gonococcal Salpingitis is less likely to Recur with Neisseria gonorrhoeae for the Same
Principal Outer Membrane Protein Antigenic Type. Am. Jr. Obstet. Gynecol.
138:978-980
23. Buchanan, T. M., W. A. Pearce 1976. Pili as Mediators of the Attachment of
Gonococci to Human Erythrocytes. Infect. Immun. 13:1483-1489
88

24. Cannon, J. G., T. M. Buchanan, and P. F. Sparling. 1983. Confirmation of
association of protein I serotype of Neisseria gonorrhoeae with ability to cause
disseminated infection. Infect. Immun. 40:816-819
25- Cannon, J. G. and P. F. Sparling. 1984. The Genetics of the Gonococcus, pp.
111-133, In: Omston, L.N., A. Balows, and P. Bauman, (eds.). Annual Reviews of
Microbiology, 38th Ed., Annual Reviews, Inc., Palo Alto, CA
26. Charlton, D. M., M. Artois, L. Prevec, J. B. Campvell, G. A.Casey, etal. 1992.
Oral Rabies Vaccination of Skunks and Foxes with a Recombinant Human Adenovirus
Vaccine, arch, virol. 123:169-179
27. Chen, C. Y., C. S. Parsons, and S. A. Morse. 1985 Membrane proteolipids of
Neisseria gonorrhoeae, pp. 360-365, In: Schoolnik, G.K., (ed.), The Pathogenic
Neisseriae, American Society for Microbiology, Washington, D C.
28. Chengalvala, M. V., B. M. Bhat, R. Bhat, M. D. Lubeck, S. Mizutani, A. R.
Davis, and P. P. Hung. 1994. Immunogenicity of High Expression
Adenovirus-Hepatitis B Virus Recombinant Vaccines in Dogs. J. Gen. Virol.
75:125-131
29. Chou, P. Y., and G. D. Fasman 1974. Prediction of Protein Conformation.
Biochem. 13:222-244
30. Cohen, M. S., P. F. Sparling 1992. Mucosal Infection with Neisseria
gonorrhoeae. Bacterial Adaptation and Mucosal Defenses. J. Clin. Invest.
89:1699-1705
31. Connell, T. D., W. J. Black, T. H. Kawula, J. A. Dempsey, K. Kvemeland, Jr.,
A. Stephenson, B. S. Schepart, G. L. Murphy, and J. G. Cannon. 1988.
Recombination among protein II genes of Neisseria gonorrhoeae generates new coding
sequences and increases structural variability in the protein n family. Mol. Microbiol.
2:227-236
32. Cooper, M. D., P. A. McGraw, and M. A. Melly 1986. Loclization of
Gonococcal LPS and its Relationship to Toxic Damage in Human Fallopian Tube
Mucosa. Infect. Immun. 51:425-430
33. Crawford, G. J. S. Knapp, J. Hale, K. K. Holmes. 1977. Asymptomatic
Gonorrhea in Men: Caused by Gonococci with Unique Nutritional Requirements.
Science 196:1352-1353

89

34. Deacon, W. E.,W. L. Peacock Jr., E. M. Freeman ef a/.. 1995. Identification of
Neisseria gonorrhoeae by means of Flourescent Antibodies. Proc. Soc. Exp. Biol.
Med. 101:322-325
35. Dorward, D.W. 1987. Characterization of naturally-elaborated outer membrane
blebs of Neisseria gonorrhoeae. University of Montana, Missoula, MT
36. Eisenberg, D , R. M. Weiss, and T. C. Terwilliger 1983. The Hydrophobic
Moment Detects Periodicity in Protein Hydrophobicity. Proc. Natl. Acad. Sci. USA
81:140-144
37. Eisenstein, B. I., T. J. Lee, and P. F. Sparling. 1977. Penicillin sensitivity and
serum resistance are independent attributes of strains of Neisseria gonorrhoeae causing
disseminated gonococcal infection. Infect. Immun. 15:834-841
38. Fischer, S. H. and R. F. Rest. 1988. Gonococci possessing only certain PII outer
membrane proteins interact with human neutrophils. Infect. Immun. 56:1574-1579
39. Forrest, B., J. T. LaBroody, S. R. Attridge, G. Boehm, L. Beyer, et al. 1989. A
Candidate Live Oral Typhoid/Cholera Hybrid Vaccine is Immunogenic in Man. J.
Infect. Dis. 159:145-146
40. Francis, M. J., G. Z. Hastings, F. Brown, J. McDermed, Y. A. Lu, and J. P.
Tam 1991. Immunological evaluation of the multiple antigen peptide (MAP) system
using the major immunogenic site of foot-and-mouth disease virus. Immunol.
73:249-254
41. Frangipane, J. V., and R. F. Rest. 1991. Increased Serum Resistance of
Gonococci Grown Anaerobically in the Presence of CMP-NANA. Infect. Immun.
42. Gamier, J. 1978. Analysis of the Accuracy and Implications of Simple Methods
for Predicting the Secondary Structure of Globular Proteins. Jr. Mol. Biol. 120:97-120
43. Giavedoni, L. D., L. Jones, M. B. Gardner, H. L. Gibson, C. T. Ng, P. J. Barr,
and T. Yilma. 1992. Vaccinia Virus recombinants expressing chimeric proteins of
human immunodeficiency virus and gamma interferon are attenuated for nude mice.
Proc. Natl. Acad. Sci. USA 89 (8):3409-3413
44 Girard, M., A. Martin, and S. Van-Der-Werf. 1993 Potential use of Poliovirus as
a Vector. Biologicals. 21 (4):371-377
45. Glynn, A. A. and M. E. Ward. 1970. Nature and heterogeneity of the antigens of
Neisseria gonorrhoeae involved in the serum bactericidal reaction. Infect. Immun.
2:162-168
90

46. Gotschlich, E. C., M. E. Seiff, and M. S. Blake. 1987. The DNA sequence of the
structural gene of gonococcal protein III and the flanking region containing a repetitive
sequence. Homology of protein III with enterobacterial OmpA proteins. Jr. Exp. Med.
165:471-482
47. Granath, W. O., Jr., F. Spray, and R. C. Judd. 1987. Analysis of Biomphalaria
glabrata (GASTROPODA) hemolymph by SDS-PAGE, HPLC, and immunoblotting.
Jr. Invert. Path. 49:198-208
48. Gregg, C. R., M. A. Melly, C. G. Hellerquest, J. G. Coniglio, Z. A. McGee.
1981. Toxic Activity of Purified LPS of Neisseria gonorrhoeae For Human Fallopian
Tube Mucosa. J. Infect. Dis. 143:432-435
49. Haas, R., S. Veit, and T. F. Meyer. 1992. Silent pilin genes of Neisseria
gonorrhoeae MS11 and the occurrence of related hypervariant sequences among other
gonococcal isolates. Mol. Microbiol. 6:197-208
50. Hagblom, P., E. Segal, E. Billyard, and M. S. So. 1985 Intragenic Recombinant
Pilus Leads to Pilus Antigenic Variation in Neisseria gonorrhoeae.. Nature(Lond)
315:156-158
51. Hagman, K. E., W. Pan, B G. Spratt, J. T. Balthazar, R. C. Judd, and W. M.
Shafer. 1995 Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic
angents is modulated by the mtrRCDE efflux system. Micro 141:1-12
52. Hale, T. L. 1990. Hybrid Vaccines using Escherichia coli as an antigen carrier.
Res. Microbiol. 141:913-919
53. Hawley, H. B., MD. 1993. Gonorrhea. Finding and Treating a Moving Target.
Postgrad. Med. 94(2):105-111
54 Hendley, J. 0-, K. R. Powell, R. Rodewald, H. H. Holzgrefe, and R. Lyles.
1977. Demonstration of A Capsule on Neisseria gonorrhoeae. N. Engl. Jr. Med.
296:608-611
55. Hildebrandt, J. F., L. M. Mayer, S. P. Wang, and T. M. Buchanan. 1978.
Neisseria gonorrhoeae acquire a new principal outer-membrane protein when
transformed to resistance to serum bactericidal activity. Infect. Immun. 20:267-273
56. Hill, S. A. and R. C. Judd. 1989. Identification and characterization of
peptidoglycan-associate proteins in Neisseria gonorrhoeae. Infect. Immun.
57:3612-3618
91

57. Hill, S. A., S. G. Morrison, and J. Swanson. 1990. The role of direct
oligonucleotide repeats in gonococcal pilin gene variation. Mol. Microbiol 4:1341-1352
58. Holmes, K. K., G. W. Counts, and H. N. Beaty. 1971. Disseminated Gonococcal
Infection. Ann. Intern. Med. 74:979-993
59. Ison, C. A., N. S. Roope, Y. Dangor, F. Radebe, and R. Ballard 1993.
Antimicrobial Susceptibilities and Serotyping of Neisseria gonorrhoeae in Southern
Africa: Influence of Geographical Source of Infection. Epidemiol-Infect.
110(2):297-305
60. Israli, C. 1921. Demonstration of Capsule-Like Appearance in Staining
Gonococci. J. Am. Med. Assoc. 76:1497
61. Jaffe, H. W., J. W. Biddle, S. R. Johnson, and P. J. Wiesner. 1980. Infections
Due to Penicillinase-Producing Neisseria gonorrhoeae in the United States. J. Infect.
Dis. 144:191-197
62. James, A. N., J. M Knox, and R. P. Williams. 1976. Attachment of Gonococci
to Sperm: Influence of Physical and Chemical Factors. Brit. Jr. Ven. Dis. 52:128-135
63 James, J. P., E. Zurlinden, C. J. Lammel, and G. F. Brooks. 1982. Relation of
protein I and colony opacity to serum killing of Neisseria gonorrhoeae. J. Infect. Dis.
145:37-44
64 James, J. T., and J. Swanson 1977. The Capsule of the Gonococcus. J. Exp. Med.
145:1082-1086
65 James-Holmquest, A. N., J. Swanson, T. M. Buchanan, R. D. Wende, and R. P.
Williams. 1974. Differential attachment by piliated and nonpiliated Neisseria
gonorrhoeae to human sperm. Infect. Immun. 9:897-902
66. Johnson, D. C. 1991. Adenovirus vectors as potential vaccines against herpes
simplex virus. Rev. Infect. Dis. 13:5912-5916
67. Johnson, S. C., R. C. Chung, C. D. Deal, J. W. Boslego, J. C. Sadoff, et al.
1991. Human Immunization with Pgh 3-2 Gonococcal Pilus Results in Cross-Reactive
Antibody to the Cyanogen Bromide Fragment-2 of Pilin. J. Infect. Dis. 163:128-134
68. Judd, R. C. 1982. Surface peptide mapping of protein I and protein III of four
strains of Neisseria gonorrhoeae. Infect. Immun 37:632-641

92

69. Judd, R. C. 1982. '^-peptide mapping of protein III isolated from four strains of
Neisseria gonorrhoeae. Infect. Immun. 37:622-631
70. Judd, R. C. 1985. Analysis of structure and surface exposure of protein lis of
Neisseria gonorrhoeae strain JS3. Infect. Immun. 48:452-457
71. Judd, R. C. 1986. Evidence for n-terminal exposure of the PIA subclass of protein
I of Neisseria gonorrhoeae. Infect. Immun. 54:408-414
72. Judd, R. C. 1987. Characterization of protein I from serum sensitive and serum
resistant transformants of Neisseria gonorrhoeae, pp. 383-392, In: Poolman, J., (ed.),
Gonococci and Meningococci, Kluwer, Dordrecht
73. Judd, R. C. 1989. Protein I: Structure, function, and genetics. Clin. Microbiol.
Rev. 2:(sup.)S48-S48
74. Judd, R. C. and S. F. Porcella. 1993. Isolation of the periplasm of Neisseria
gonorrhoeae. Mol. Microbiol. 10:In press
75. Judd, R. C. and W. M. Shafer. 1989. Topographical alterations of protein I of
Neisseria gonorrhoeae correlated with lipooligosaccharide variations. Mol. Microbiol.
3:637-643
76. Kasper, D L. and P. A. Rice. 1978. Antigenic specificity of lipopolysaccharide to
bactericidal antibody response in gonococcal infection. Brooks, G.F., E C. Gotschlich,
F.E. Young, W.D. Sawyer, and K.K. Holmes, (eds.), Immunobiology of Neisseria
gonorrhoeae, American Society for Microbiology , Washington, D C.
77. Kellogg, D. S. Jr., W. L. Peacock Jr., W. E. Deacon, L. Brown, and C. I.
Pirkle. 1963. Neisseria gonorrhoeae. I. Virulence Genetically Linked to Clonal
Variation. J. Bacteriol. 85:1274-1279
78. Kerwood, D E., H. Schneider, and R. Yamasaki. 1992. Structural analysis of
lipooligosaccharide produced by Neisseria gonorrhoeae, strain MSllmk (variant A): a
precursor for a gonococcal lipooligosaccharide associated with virulence. Biochem.
31:12760-12768
79. Klein, J. R., B. H. Henrich, and R. Plapp. 1991. Molecular analysis and
Nucleotide Sequence of the envCD Operon of Escherichia coli. Mol. Gen. Genet.
230:230-240
80. Knapp, J. S. and K. K. Holmes. 1975. Disseminated gonococcal infections caused
by Neisseria gonorrhoeae with unique nutritional requirements. J. Infect. Dis.
93

132:204-208
81. Kyte, J., and R. F. Doolittle 1982. A Simple Method for Displaying the
Hydrophobic Character of a Protein. Jr. Mol. Biol. 157:105-132
82. Lambden, P. R., J. E. Heckels, L.T. James, and P. J. Watt. 1979. Variations in
surface protein composition associated with virulence properties in opacity types of
Neisseria gonorrhoeae. Jr. Gen. Microbiol. 114:305-312
83. Ma, D., D. N. Cook, M. Alberti, N. G. Pon, H. Nikiado, and J. E. Hearst. 1993.
Molecular cloning and characterization of acr and acrE genes of Escherichia coli. J.
Bacteriol. 175:6299-6313
84. Mardh, P. A. and L. Westrom. 1976. Adherence of bacteria to vaginal epithelial
cells. Infect. Immun. 13:661-666
85 McDade, R. L., and K. H. Johnston 1980. Characterization of Serologically
Dominant Outer Membrane Proteins of Nesseria gonorrhoeae. J. Bacteriol. 141:1183
86. McGee, Z. A., A. P. Johnson, and D. Taylor-Robinson. 1981. Pathogenic
Mechanisms of Neisseria gonorrhoeae: Observations on Damage to Human Fallopian
Tubes in Organ Culture by Gonococci of Colony Typel or Type4. J. Infect. Dis.
143:413-422
87. Mintz, C. S., M. A. Apicella, and S. A. Morse. 1984 Electrophoretic and
serological characterization of the lipopolysaccharide produced by Neisseria
gonorrhoeae. J. Infect. Dis. 149:544-552
88. Morin, J. E., M. D. Lubeck, J. E. Burton, A. J. Conley, A. R. Davis, and P. P.
Hung. 1987. Recombinant adenovirus induces antibody responses to hepatitis B virus
surface antigens in hampsters. Proc. Natl. Acad. Sci. USA 84:4626-4630
89. Morse, S. A. and M. A. Apicella. 1982. Isolation of a lipopolysaccharide mutant
of Neisseria gonorrhoeae: an analysis of the antigenic and biologic differences. J.
Infect. Dis. 145:206-216
90. Mulks, M. H. and A. G. Plaut. 1978. IgA protease production as a characteristic
distinguishing pathogenic from harmless Neisseriaceae. N. Engl. Jr. Med. 299:973-976

91. Murphy, G. L., T. D. Connel, D S. Barrit, M. Koomey, and J. G. Cannon.
1989. Phase Variatin of Gonococcal Proteinll: Regulation of Gene Expression by
Slipped-Stranded Mispairing of a Repetative DNA Sequence. Cell 56:539-547
94

92. Natuk, R. J., P. K. Chanda, M. D. Lubeck, A. R. Davis, J. Wilhelm, etal. 1992.
Adenovirus-Human Immunodeficiency Virus (HIV) Envelope Recombinant Vaccines
Elicit High-Titered HIV-Neutralizing Antibodies in the Dog Model. Proc. Natl. Acad.
Sci. USA 89 (16):7777-7781
93- Nikaido, H. 1994. Prevention of drug access to bacterial targets: permeability
barriers and active efflux. Science 264:382-388
94. O Brian, J. P., D L. Goldenberg, and P. A. Rice. 1983. Disseminated
gonococcal infection: a prospective analysis of 49 patients and a review of
pathophysiology and immune mechanisms. Medicine (Baltimore) 62:395-406
95. Paavanen J, K. Teisala, P. K. Heinonen, R. Aine, S. Laine, M.Lehtinen, et al.
1987. Microbiological and Histopathological Findings in Acute Pelvic Inflammatory
Disease. Br J Obsted Gynaecol 94:454-460
96. Perine, P. L., C. Thomsbury, W. Schalla, J. Biddle, and M. S. Siegal 1977.
Evidence for Two Distinct Types of Penicillin-Producing Neisseria gonorrhoeae.
Lancet 2:993-995
97. Pettit, R. K., J. C. Szuba, and R. C. Judd. 1990. Comparison of two serum
bactericidal assays for Neisseria gonorrhoeae. Jr. Immun. Meth. 129:15-22
98. Phillips, I. 1976. B-Lactamase-Producing Penicillin-Resistance gonococcus.
Lancet 2:656-657
99. Piatt, R., P. A. Rice, and W. M. McCormack. 1983 Risk of Acquiring
Gonorrhea and Prevalence of Abnormal Adnexal Findings Among Women recently
Exposed To Gonorrhea. JAMA 250:3205-3209
100. Plaut, A. G., J. V. Gilbert, and R. Wistar Jr. 1977. Loss of Antibody Activity in
Human Immunoglobulin A Exposed to Extracellular Immunoglobulin A Proteases of
Neisseria gonorrhoeae and Streptococcus sanguis. Infect. Immun. 17:130-135
101. Plummer, F. A., H. Chubb, J. N. Simonsen, M. Bosire, L. Slaney, I. Maclean,
J. O. Ndinya-Achola, P. Waiyaki, and R. C. Brunham. 1993 Antibody to Rmp (outer
membrane protein 3) increases susceptibility to gonococcal infection. J. Clin. Invest.
91:339-343
102. Plummer, F. A., J. N. Simonsen, H. Chubb, L. Slaney, J. Kimata, M. Bosire, J.
O. Ndinya-Achola, and E. N. Ngugi. 1989. Epidemiologic evidence for the
development of serovar-specific immunity after gonococcal infection. J. Clin. Invest.
95

83:1472-1476
103. Porcella, S. F. and R. C. Judd. 1992. Polyclonal antibody characterization of the
conserved outer membrane protein of Neisseria gonorrhoeae and Neisseria
meningitidis, Conde Glez, C., (ed.). Proceedings of the Eighth International
Conference on Pathogenic Neisseria, In press,
104. Porcella, S.P. 1994 Characterization of Three 44kDa Proteins of Neisseria
gonorrhoeae, PhD thesis. University of Montana, Missoula MT.
105. Posnett, D. N., H. McGrath, and J. P. Tam 1988. A Novel Method for
Producing Anti-peptide Antibodies. J. Biol. Chem. 263 (4):1719-1725
106. Punsalang, A. P. Jr., W. D. Sawyer. 1973. Role of Pili in the Virulence of
Neisseria gonorrhoeae. Infect. Immun. 13:661-666
107. Rabinovich, N. R., P. Mclnnes, D. L. Klein, and B. R. Hall. 1994 Vaccine
Technologies: View to the Future. Science 265:1401-1404
108. Rice, P. A., H. E. Vayo, M. R. Tam, and M. S. Blake. 1986. Immunoglobulin G
antibodies directed against protein III block killing of serum-resistant Neisseria
gonorrhoeae by immune serum. Jr. Exp. Med. 164:1735-1748
109. Rice, R. J. 1992. Antimicrobial resistance in Neisseria gonorrhoeae. Cleve. Clin.
J. Med. 59:97-98
110. Richardson, W. P., and J. C. Sadoff. 1977. Production of a Capsule by Neisseria
gonorrhoeae.. Infect. Immun. 15:663-664
111. Riggs, P. 1994 Expression and purification of Maltose Binding Protein Fusions,
pp. 16.6.1-16.6.14, In: R.M.Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G
Seidman, J. A. Smith and K. S. Struhl, (ed.). Current Protocols in Molecular Biology,
John Wiley and Sons, Inc., New York
112. Robinson, E. J., C. M. Clemens, G. K. Schoolnik, and Z. A. McGee. 1989.
Probing the Surface of Neisseria gonorrhoeae: Immunoelectron Microscopic Studies to
Localize Cyanogen Bromide Fragment 2 in Gonococcal Pili. Mol. Microbiol. 3:57-64
113 Robinson, E. N., Jr., C. M. Clemens, Z. A. McGee, and J. G Cannon. 1988.
Immunoelectron microscopic localization of outer membrane proteins II on the surface
of Neisseria gonorrhoeae. Infect. Immun. 56:1003-1006
114 Rockhill, R. C., B. Leksana, U. Wijaya, D Montosudarmo, W. Soekanto, and
96

r
W. WideJatno 1982. . S. E. AsianJ. Trop. Med. 13:96-99
115. Rossman, M. G. 1989. The Canyon Hypothesis. Viral-Immunol 2(3):143-161
116. Rothbarb, J. B., R. Fernandez, and G. K. Schoolnik. 1984. Strain Specific and
Common Epitopes of Gonococcal Pili. J. Exp. Med. 160:208-221
117. Salit, I. E., M. S. Blake, and E. C. Gotschlich 1980. Intra-Strain Heterogeneity
of Gonococcal Pili is Related to Opacity Colony Variance. J. Exp. Med. 151:716-725
118. Sarafian, S. K., M. R. Tarn, and S. A. Morse. 1983. Gonococcal protein
I-specific opsonic IgG in normal human serum. J. Infect. Dis. 148:1025-1032
119. Schneider, H. 1991. Expression of Paraglaboside-Like LOS May be a Neccessary
Component of Gonococcal Pathogenesis in Men. J. Exp. Med. 174:1601-1606
120. Schneider, H., T. L. Hale, W. D. Zollinger, R. C. Seid, Jr., C. A. Hammack,
and J. M. Griffiss. 1984 Heterogeneity of molecular size and antigenic expression
within lipooligosaccharides of individual strains of Neisseria gonorrhoeae and
Neisseria meningitidis. Infect. Immun. 45:544-549
121. Schneider, H., C. A. Hammack, M. A. Apicella, and J. M. Griffiss. 1988.
Instability of Expression of LOS and Their Epitopes in Neisseria gonorrhoeae. Infect.
Immun. 56:942
122. Schneider, H., J. McLeod Griffiss, G. D Williams, and G. B. Pier 1982.
Immunological Basis of Serum Resistance of Neisseria gonorrhoeae. Jr. Gen.
Microbiol. 128:13-22
123. Schoolnik, G. K., R. Fernandez, J. Y. Tai, J. B. Rothbard, and E. C. Gotschlich.
1984 Gonococcal pili. Primary structure and receptor binding domain. Jr. Exp. Med.
159:1351-1370
124. Schoolnik, G. K., J. Y. Tai, and E. C. Gotschlich. 1983. A Pilus Peptide Vaccine
for the Prevention of Gonorrhea. Prog. Allergy 33:314-331
125. Segal, E., P. Hagblom, H. S. Seifert, and M. S. So. 19. Antigenic Variation of
Gonococcal Pilus Involves Assembly of Separated Silent Gene Segments. Proc. Natl.
Acad. Sci. U. S. A. 83:2177-2181
126. Service, R. F. 1994. Triggering the First Line of Defense. Science
265:1522-1524

97

127. Shafèr, W. M., K. A. Joiner, L. F. Guymon, M. S. Cohen, and P. F. Sparling.
1984. Serum sensitivity of Neisseria gonorrhoeae: the role of lipopolysaccharide. J.
Infect. Dis. 149:175-183
128. So, M., E. Billyard, C. Deal, I. Getzoff, P. Hagblom, T. F. Meyer, E. Segal,
and J. Tainer. 1985. Gonococcal Pilus; Genetics and Structure. Curr. Top. Microbiol.
Immunol. 118:13-28
129. Sory, M. P., and G. R. Comelis. 1990. Delivery of the Cholera Toxin B Subunit
by using a Recombinant Yersinia enterocolitica Strain as a Live Oral Carrier. Res.
Microbiol. 141:921-929
130. Sparling P. F., C. Elkins, P. B. Wyrick, and M. S. Cohen. 1994. Vaccines for
Sexually Transmitted Infections: A Realistic Goal? Proc. Natl. Acad. Sci. USA 91
(7):2456-2463
131. Sparling, P. F., J. G. Cannon, and M. So. 1986. Phase and antigenic variation of
pili and outer membrane protein II of Neisseria gonorrhoeae. J. Infect. Dis.
153:196-201
132. Swanson, J. 1973. Studies on Gonococcal Infection IV. Pili: Their Role in
Attachment of Gonococci to Tissue Culture Cells. J. Exp. Med. 137:571-589
133. Swanson, J. 1978. Studies on gonococcus infection. Xn. Colony color and
opacity variants of gonococci. Infect. Immun. 19:320-331
134. Swanson, J. 1981. Surface-exposed protein antigens of the gonococcal outer
membrane. Infect. Immun. 34:804-816
135. Swanson, J. 1982. Colony opacity and Protein II compositions of gonococci.
Infect. Immun. 37:359-368
136. Swanson, J., G. King, and B. Zeligs. 1975. Studies on gonococcus infection.
Vni. ^"Iodine labeling of gonococci and studies on their in vitro interactions with
eukaryotic cells. Infect. Immun. 11:453-459
137. Swanson, J., S. J. Krause, and E. C. Gotschlich. 1971. Studies on gonococcus
infection. I. Pili and zones of adhesion: their relation to gonococcal growth patterns.
Jr. Exp. Med. 134:886-906
138. Swanson, J., L. M. Mayer, and M. R. Tam. 1982. Antigenicity of Neisseria
gonorrhoeae outer membrane proteins III detected by immunoprecipitation and western
blot transfer with monoclonal antibody. Infect. Immun. 38:668-672
98

139. Swanson, J., K. Robbins, O. B. Barrera, D Corwin, J. W. Boslego, J. Ciak, M.
S. Blake, and J. M. Koomey. 1987. Gonococcal pilin variants in experimental
gonorrhea. J. Exp. Med. 165:1344-1357
140. Thongthai, C., and W. D. Sawyer. 1973. Studies on the Virulence of Neisseria
gonorrhoeae. I. Relation of Colonial Morphology and Resistance to Phagocystosis by
Polymorphonuclear Leukocytes. Infect. Immun. 7:373-379
141. Tinsley, C. R., and E. C. Gotschlich 1995. Cloning and characterization of the
Meningococcal Polyphosphate Kinase Gene: Production of Polyphosphate Synthesis
Mutants. Infect. Immun. 63 (5): 1624-1630
142. Virji, M. and J. E. Heckels 1986. The Effects of PII and Pili on the Interaction of
Neisseria gonorrhoeae with Human Polymorphonuclear Leucocytes. J. Gen Microbiol.
132:503-512
143. Ward, M. E., P. J. Watt, and J. N. Robertson 1974 The Human Fallopian Tube;
a Laboratory Model for Gonococcal Infection. J. Infect. Dis. 129:650-659
144. Washington, A. E. 1982. Update on Treatment Recommendations for Gonococcal
Infections. Rev. Infect. Dis. 4:758-771
145. Washington, A. E., and P. Katz, 1991. Cost of and payment source for pelvic
inflammatory disease. Trends and projections, 1983 through 2000. JAMA
266:2565-2569
146. Westrom, L., and P. H. Wolner 1993 Pathogenesis of Pelvic inflammatory
Disease. Genitourin. Med. 69:9-17
147. Wetzler, L. M., M. S. Blake, K. Barry, and E. C. Gotschlich. 1992. Gonococcal
porin vaccine evaluation: comparison of Por proteosomes, liposomes, and blebs
isolated from rmp deletion mutants. J. Infect. Dis. 166:551 555
148. Wetzler, L. M., M. S. Blake, and E. C. Gotschlich. 1989. Protein I (Por) of
Neisseria gonorrhoeae as an immunogen: liposomes, proteosomes, and the lack of
blocking antibodies. Trans. Assoc. Am. Physicians 102:78-90
149. Zak, K., J. L. Diaz, D. Jackson, and J. E. Heckels. 1984. Antigenic variation
during infection with Neisseria gonorrhoeae: detection of antibodies to surface proteins
in sera of patients with gonorrhea. J. Infect. Dis. 149:166-174

99

150. Zhang, Q. Y., D. DeRyckere, P. Lauer, and M. Koomey. 1992. Gene conversion
in Neisseria gonorrhoeae: evidence for its role in pilus antigenic variation. Proc. Natl.
Acad. Sci. U. S. A. 89:5366-5370

100

